HRP20110128T1 - Substituirani pirazolopirimidini, postupak njihove pripreme i njihova upotreba kao lijek - Google Patents
Substituirani pirazolopirimidini, postupak njihove pripreme i njihova upotreba kao lijek Download PDFInfo
- Publication number
- HRP20110128T1 HRP20110128T1 HR20110128T HRP20110128T HRP20110128T1 HR P20110128 T1 HRP20110128 T1 HR P20110128T1 HR 20110128 T HR20110128 T HR 20110128T HR P20110128 T HRP20110128 T HR P20110128T HR P20110128 T1 HRP20110128 T1 HR P20110128T1
- Authority
- HR
- Croatia
- Prior art keywords
- pyrazolo
- methanone
- dihydro
- isoquinolin
- pyrimidin
- Prior art date
Links
- 239000003814 drug Substances 0.000 title claims 7
- 238000002360 preparation method Methods 0.000 title claims 4
- 238000000034 method Methods 0.000 title claims 2
- APXRHPDHORGIEB-UHFFFAOYSA-N 1H-pyrazolo[4,3-d]pyrimidine Chemical class N1=CN=C2C=NNC2=C1 APXRHPDHORGIEB-UHFFFAOYSA-N 0.000 title 1
- -1 pyrazolopyrimidine compound Chemical class 0.000 claims abstract 43
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract 17
- 239000001257 hydrogen Substances 0.000 claims abstract 17
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims abstract 16
- 229910052799 carbon Inorganic materials 0.000 claims abstract 15
- 150000001721 carbon Chemical group 0.000 claims abstract 15
- 150000002431 hydrogen Chemical class 0.000 claims abstract 14
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims abstract 13
- 125000000217 alkyl group Chemical group 0.000 claims abstract 10
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims abstract 9
- 125000000623 heterocyclic group Chemical group 0.000 claims abstract 7
- 125000004093 cyano group Chemical group *C#N 0.000 claims abstract 6
- 229910052736 halogen Inorganic materials 0.000 claims abstract 6
- 150000002367 halogens Chemical class 0.000 claims abstract 6
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims abstract 6
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims abstract 6
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims abstract 5
- 125000001072 heteroaryl group Chemical group 0.000 claims abstract 5
- 125000005222 heteroarylaminocarbonyl group Chemical group 0.000 claims abstract 5
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims abstract 4
- 125000001246 bromo group Chemical group Br* 0.000 claims abstract 4
- 125000001309 chloro group Chemical group Cl* 0.000 claims abstract 4
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims abstract 3
- 125000003320 C2-C6 alkenyloxy group Chemical group 0.000 claims abstract 3
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims abstract 3
- 125000002252 acyl group Chemical group 0.000 claims abstract 3
- 125000004442 acylamino group Chemical group 0.000 claims abstract 3
- 125000004423 acyloxy group Chemical group 0.000 claims abstract 3
- 125000005100 aryl amino carbonyl group Chemical group 0.000 claims abstract 3
- 125000003118 aryl group Chemical group 0.000 claims abstract 3
- 125000005161 aryl oxy carbonyl group Chemical group 0.000 claims abstract 3
- 125000004104 aryloxy group Chemical group 0.000 claims abstract 3
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims abstract 3
- 125000004986 diarylamino group Chemical group 0.000 claims abstract 3
- 125000005241 heteroarylamino group Chemical group 0.000 claims abstract 3
- 125000005553 heteroaryloxy group Chemical group 0.000 claims abstract 3
- 125000005226 heteroaryloxycarbonyl group Chemical group 0.000 claims abstract 3
- 125000005844 heterocyclyloxy group Chemical group 0.000 claims abstract 3
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims abstract 2
- 150000001875 compounds Chemical class 0.000 claims 28
- 208000012661 Dyskinesia Diseases 0.000 claims 12
- 206010012289 Dementia Diseases 0.000 claims 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 8
- 150000003839 salts Chemical class 0.000 claims 8
- 208000002193 Pain Diseases 0.000 claims 7
- 230000003287 optical effect Effects 0.000 claims 7
- 208000019901 Anxiety disease Diseases 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 6
- 150000004677 hydrates Chemical class 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 208000018737 Parkinson disease Diseases 0.000 claims 5
- 206010041250 Social phobia Diseases 0.000 claims 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 5
- 208000019906 panic disease Diseases 0.000 claims 5
- 208000023105 Huntington disease Diseases 0.000 claims 4
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 claims 4
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 claims 4
- 208000008589 Obesity Diseases 0.000 claims 4
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims 4
- 208000010877 cognitive disease Diseases 0.000 claims 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 4
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 4
- 208000004296 neuralgia Diseases 0.000 claims 4
- 208000021722 neuropathic pain Diseases 0.000 claims 4
- 235000020824 obesity Nutrition 0.000 claims 4
- PPFVMPKRZPPZFQ-UHFFFAOYSA-N (6-bromopyrazolo[1,5-a]pyrimidin-2-yl)-(3,4-dihydro-1h-isoquinolin-2-yl)methanone Chemical compound C1CC2=CC=CC=C2CN1C(=O)C1=NN(C=C(Br)C=N2)C2=C1 PPFVMPKRZPPZFQ-UHFFFAOYSA-N 0.000 claims 3
- 125000004738 (C1-C6) alkyl sulfinyl group Chemical group 0.000 claims 3
- 208000024827 Alzheimer disease Diseases 0.000 claims 3
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 3
- 208000003251 Pruritus Diseases 0.000 claims 3
- 208000009205 Tinnitus Diseases 0.000 claims 3
- 230000007278 cognition impairment Effects 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- 210000003027 ear inner Anatomy 0.000 claims 3
- 208000021302 gastroesophageal reflux disease Diseases 0.000 claims 3
- 208000028173 post-traumatic stress disease Diseases 0.000 claims 3
- 201000000980 schizophrenia Diseases 0.000 claims 3
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 3
- 239000000126 substance Substances 0.000 claims 3
- 208000011580 syndromic disease Diseases 0.000 claims 3
- 231100000886 tinnitus Toxicity 0.000 claims 3
- 125000004845 (C1-C6) alkylsulfonylamino group Chemical group 0.000 claims 2
- NWEDYYWQOARMLJ-UHFFFAOYSA-N 2-(6-bromopyrazolo[1,5-a]pyrimidine-2-carbonyl)-3,4-dihydro-1h-isoquinoline-7-carbonitrile Chemical compound C1CC2=CC=C(C#N)C=C2CN1C(=O)C1=NN(C=C(Br)C=N2)C2=C1 NWEDYYWQOARMLJ-UHFFFAOYSA-N 0.000 claims 2
- 206010065040 AIDS dementia complex Diseases 0.000 claims 2
- 208000007848 Alcoholism Diseases 0.000 claims 2
- 208000029197 Amphetamine-Related disease Diseases 0.000 claims 2
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 2
- 208000014644 Brain disease Diseases 0.000 claims 2
- 206010050389 Cerebral ataxia Diseases 0.000 claims 2
- 208000000094 Chronic Pain Diseases 0.000 claims 2
- 208000022497 Cocaine-Related disease Diseases 0.000 claims 2
- 208000028698 Cognitive impairment Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 206010010904 Convulsion Diseases 0.000 claims 2
- 206010013654 Drug abuse Diseases 0.000 claims 2
- 206010059866 Drug resistance Diseases 0.000 claims 2
- 208000014094 Dystonic disease Diseases 0.000 claims 2
- 208000030814 Eating disease Diseases 0.000 claims 2
- 208000032274 Encephalopathy Diseases 0.000 claims 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 2
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims 2
- 208000011688 Generalised anxiety disease Diseases 0.000 claims 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 208000004454 Hyperalgesia Diseases 0.000 claims 2
- 206010065390 Inflammatory pain Diseases 0.000 claims 2
- 208000006264 Korsakoff syndrome Diseases 0.000 claims 2
- 208000019695 Migraine disease Diseases 0.000 claims 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims 2
- 208000026251 Opioid-Related disease Diseases 0.000 claims 2
- 208000028017 Psychotic disease Diseases 0.000 claims 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 claims 2
- 208000005793 Restless legs syndrome Diseases 0.000 claims 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 claims 2
- 208000018756 Variant Creutzfeldt-Jakob disease Diseases 0.000 claims 2
- 201000004810 Vascular dementia Diseases 0.000 claims 2
- 239000013543 active substance Substances 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 2
- 230000036506 anxiety Effects 0.000 claims 2
- 125000005135 aryl sulfinyl group Chemical group 0.000 claims 2
- 125000004657 aryl sulfonyl amino group Chemical group 0.000 claims 2
- 125000004391 aryl sulfonyl group Chemical group 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 2
- 208000014679 binge eating disease Diseases 0.000 claims 2
- 208000005881 bovine spongiform encephalopathy Diseases 0.000 claims 2
- 210000004556 brain Anatomy 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- 230000036461 convulsion Effects 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 125000005240 diheteroarylamino group Chemical group 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 235000014632 disordered eating Nutrition 0.000 claims 2
- 206010015037 epilepsy Diseases 0.000 claims 2
- 208000030533 eye disease Diseases 0.000 claims 2
- 208000029364 generalized anxiety disease Diseases 0.000 claims 2
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 claims 2
- 210000003128 head Anatomy 0.000 claims 2
- 125000005150 heteroarylsulfinyl group Chemical group 0.000 claims 2
- 125000005143 heteroarylsulfonyl group Chemical group 0.000 claims 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 2
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 claims 2
- 208000014674 injury Diseases 0.000 claims 2
- 208000028867 ischemia Diseases 0.000 claims 2
- 230000007803 itching Effects 0.000 claims 2
- 210000000111 lower esophageal sphincter Anatomy 0.000 claims 2
- 208000024714 major depressive disease Diseases 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 206010027599 migraine Diseases 0.000 claims 2
- 208000027061 mild cognitive impairment Diseases 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 238000010992 reflux Methods 0.000 claims 2
- 201000009032 substance abuse Diseases 0.000 claims 2
- 208000024891 symptom Diseases 0.000 claims 2
- 238000002560 therapeutic procedure Methods 0.000 claims 2
- 230000008733 trauma Effects 0.000 claims 2
- SWOCEYHDJVDYOB-UHFFFAOYSA-N (5-bromo-1-methyl-3,4-dihydro-1h-isoquinolin-2-yl)-(6-bromopyrazolo[1,5-a]pyrimidin-2-yl)methanone Chemical compound C1=C2N=CC(Br)=CN2N=C1C(=O)N1C(C)C2=CC=CC(Br)=C2CC1 SWOCEYHDJVDYOB-UHFFFAOYSA-N 0.000 claims 1
- HHXZIUZTNKMHAD-UHFFFAOYSA-N (5-bromo-1-methyl-3,4-dihydro-1h-isoquinolin-2-yl)-(6-chloropyrazolo[1,5-a]pyrimidin-2-yl)methanone Chemical compound C1=C2N=CC(Cl)=CN2N=C1C(=O)N1C(C)C2=CC=CC(Br)=C2CC1 HHXZIUZTNKMHAD-UHFFFAOYSA-N 0.000 claims 1
- YUPGMVDKCNVPSC-UHFFFAOYSA-N (6-bromo-3,4-dihydro-1h-isoquinolin-2-yl)-(6-bromopyrazolo[1,5-a]pyrimidin-2-yl)methanone Chemical compound C1=C2N=CC(Br)=CN2N=C1C(=O)N1CC2=CC=C(Br)C=C2CC1 YUPGMVDKCNVPSC-UHFFFAOYSA-N 0.000 claims 1
- XUNIPZVSSDYWSX-UHFFFAOYSA-N (6-bromopyrazolo[1,5-a]pyrimidin-2-yl)-(1,5-dimethyl-3,4-dihydro-1h-isoquinolin-2-yl)methanone Chemical compound C1=C2N=CC(Br)=CN2N=C1C(=O)N1C(C)C2=CC=CC(C)=C2CC1 XUNIPZVSSDYWSX-UHFFFAOYSA-N 0.000 claims 1
- NRZIUDUHTXAZNJ-UHFFFAOYSA-N (6-bromopyrazolo[1,5-a]pyrimidin-2-yl)-(1-ethyl-3,4-dihydro-1h-isoquinolin-2-yl)methanone Chemical compound C1=C2N=CC(Br)=CN2N=C1C(=O)N1C(CC)C2=CC=CC=C2CC1 NRZIUDUHTXAZNJ-UHFFFAOYSA-N 0.000 claims 1
- HTSJIPYYDHSPSC-UHFFFAOYSA-N (6-bromopyrazolo[1,5-a]pyrimidin-2-yl)-(1-methyl-5-methylsulfonyl-3,4-dihydro-1h-isoquinolin-2-yl)methanone Chemical compound C1=C2N=CC(Br)=CN2N=C1C(=O)N1C(C)C(C=CC=C2S(C)(=O)=O)=C2CC1 HTSJIPYYDHSPSC-UHFFFAOYSA-N 0.000 claims 1
- ATQIIICOFOXLKD-UHFFFAOYSA-N (6-bromopyrazolo[1,5-a]pyrimidin-2-yl)-(1-methyl-5-morpholin-4-yl-3,4-dihydro-1h-isoquinolin-2-yl)methanone Chemical compound CC1N(C(=O)C2=NN3C=C(Br)C=NC3=C2)CCC2=C1C=CC=C2N1CCOCC1 ATQIIICOFOXLKD-UHFFFAOYSA-N 0.000 claims 1
- YPCXOLQQMFLNOS-UHFFFAOYSA-N (6-bromopyrazolo[1,5-a]pyrimidin-2-yl)-(1-methyl-5-nitro-3,4-dihydro-1h-isoquinolin-2-yl)methanone Chemical compound C1=C2N=CC(Br)=CN2N=C1C(=O)N1C(C)C(C=CC=C2[N+]([O-])=O)=C2CC1 YPCXOLQQMFLNOS-UHFFFAOYSA-N 0.000 claims 1
- LCUNXCALWIUFFY-UHFFFAOYSA-N (6-bromopyrazolo[1,5-a]pyrimidin-2-yl)-(1-methyl-5-pyridin-4-yl-3,4-dihydro-1h-isoquinolin-2-yl)methanone Chemical compound CC1N(C(=O)C2=NN3C=C(Br)C=NC3=C2)CCC2=C1C=CC=C2C1=CC=NC=C1 LCUNXCALWIUFFY-UHFFFAOYSA-N 0.000 claims 1
- WELFXGNWGDVVMR-UHFFFAOYSA-N (6-bromopyrazolo[1,5-a]pyrimidin-2-yl)-(1-methyl-5-pyrimidin-5-yl-3,4-dihydro-1h-isoquinolin-2-yl)methanone Chemical compound CC1N(C(=O)C2=NN3C=C(Br)C=NC3=C2)CCC2=C1C=CC=C2C1=CN=CN=C1 WELFXGNWGDVVMR-UHFFFAOYSA-N 0.000 claims 1
- CFOQZJSPTFWRDL-UHFFFAOYSA-N (6-bromopyrazolo[1,5-a]pyrimidin-2-yl)-(1-methyl-6-methylsulfonyl-3,4-dihydro-1h-isoquinolin-2-yl)methanone Chemical compound C1=C2N=CC(Br)=CN2N=C1C(=O)N1C(C)C2=CC=C(S(C)(=O)=O)C=C2CC1 CFOQZJSPTFWRDL-UHFFFAOYSA-N 0.000 claims 1
- YISXYPYGHRSNNW-UHFFFAOYSA-N (6-bromopyrazolo[1,5-a]pyrimidin-2-yl)-(1-methyl-6-morpholin-4-yl-3,4-dihydro-1h-isoquinolin-2-yl)methanone Chemical compound C=1C=C2C(C)N(C(=O)C3=NN4C=C(Br)C=NC4=C3)CCC2=CC=1N1CCOCC1 YISXYPYGHRSNNW-UHFFFAOYSA-N 0.000 claims 1
- UPARMMHHPILIJC-UHFFFAOYSA-N (6-bromopyrazolo[1,5-a]pyrimidin-2-yl)-(1-methyl-6-nitro-3,4-dihydro-1h-isoquinolin-2-yl)methanone Chemical compound C1=C2N=CC(Br)=CN2N=C1C(=O)N1C(C)C2=CC=C([N+]([O-])=O)C=C2CC1 UPARMMHHPILIJC-UHFFFAOYSA-N 0.000 claims 1
- JIQLQZOKWHQZCX-UHFFFAOYSA-N (6-bromopyrazolo[1,5-a]pyrimidin-2-yl)-(1-methyl-6-pyridin-2-yl-3,4-dihydro-1h-isoquinolin-2-yl)methanone Chemical compound C=1C=C2C(C)N(C(=O)C3=NN4C=C(Br)C=NC4=C3)CCC2=CC=1C1=CC=CC=N1 JIQLQZOKWHQZCX-UHFFFAOYSA-N 0.000 claims 1
- COMTUZGZYWLESD-UHFFFAOYSA-N (6-bromopyrazolo[1,5-a]pyrimidin-2-yl)-(1-methyl-6-pyridin-4-yl-3,4-dihydro-1h-isoquinolin-2-yl)methanone Chemical compound C=1C=C2C(C)N(C(=O)C3=NN4C=C(Br)C=NC4=C3)CCC2=CC=1C1=CC=NC=C1 COMTUZGZYWLESD-UHFFFAOYSA-N 0.000 claims 1
- PWGPITRMFIVJNU-UHFFFAOYSA-N (6-bromopyrazolo[1,5-a]pyrimidin-2-yl)-(1-methyl-6-pyrimidin-5-yl-3,4-dihydro-1h-isoquinolin-2-yl)methanone Chemical compound C=1C=C2C(C)N(C(=O)C3=NN4C=C(Br)C=NC4=C3)CCC2=CC=1C1=CN=CN=C1 PWGPITRMFIVJNU-UHFFFAOYSA-N 0.000 claims 1
- JZDBWFGAUFJPQA-UHFFFAOYSA-N (6-bromopyrazolo[1,5-a]pyrimidin-2-yl)-(1-methyl-7-methylsulfonyl-3,4-dihydro-1h-isoquinolin-2-yl)methanone Chemical compound C1=C2N=CC(Br)=CN2N=C1C(=O)N1C(C)C2=CC(S(C)(=O)=O)=CC=C2CC1 JZDBWFGAUFJPQA-UHFFFAOYSA-N 0.000 claims 1
- FWEZHCBRRIBOAO-UHFFFAOYSA-N (6-bromopyrazolo[1,5-a]pyrimidin-2-yl)-(1-methyl-7-morpholin-4-yl-3,4-dihydro-1h-isoquinolin-2-yl)methanone Chemical compound C1=C2C(C)N(C(=O)C3=NN4C=C(Br)C=NC4=C3)CCC2=CC=C1N1CCOCC1 FWEZHCBRRIBOAO-UHFFFAOYSA-N 0.000 claims 1
- DTCUICSZBDQWLM-UHFFFAOYSA-N (6-bromopyrazolo[1,5-a]pyrimidin-2-yl)-(1-methyl-7-nitro-3,4-dihydro-1h-isoquinolin-2-yl)methanone Chemical compound C1=C2N=CC(Br)=CN2N=C1C(=O)N1C(C)C2=CC([N+]([O-])=O)=CC=C2CC1 DTCUICSZBDQWLM-UHFFFAOYSA-N 0.000 claims 1
- MQWMHGJUIVJPMH-UHFFFAOYSA-N (6-bromopyrazolo[1,5-a]pyrimidin-2-yl)-(1-methyl-7-piperidin-1-yl-3,4-dihydro-1h-isoquinolin-2-yl)methanone Chemical compound C1=C2C(C)N(C(=O)C3=NN4C=C(Br)C=NC4=C3)CCC2=CC=C1N1CCCCC1 MQWMHGJUIVJPMH-UHFFFAOYSA-N 0.000 claims 1
- KIJSFZQEZKRICU-UHFFFAOYSA-N (6-bromopyrazolo[1,5-a]pyrimidin-2-yl)-(1-methyl-7-pyridin-4-yl-3,4-dihydro-1h-isoquinolin-2-yl)methanone Chemical compound C1=C2C(C)N(C(=O)C3=NN4C=C(Br)C=NC4=C3)CCC2=CC=C1C1=CC=NC=C1 KIJSFZQEZKRICU-UHFFFAOYSA-N 0.000 claims 1
- XNONYRUJWSZRMM-UHFFFAOYSA-N (6-bromopyrazolo[1,5-a]pyrimidin-2-yl)-(1-methyl-7-pyrimidin-5-yl-3,4-dihydro-1h-isoquinolin-2-yl)methanone Chemical compound C1=C2C(C)N(C(=O)C3=NN4C=C(Br)C=NC4=C3)CCC2=CC=C1C1=CN=CN=C1 XNONYRUJWSZRMM-UHFFFAOYSA-N 0.000 claims 1
- XSDZFPJQVQSKGP-UHFFFAOYSA-N (6-bromopyrazolo[1,5-a]pyrimidin-2-yl)-(1-methyl-7-pyrrolidin-1-yl-3,4-dihydro-1h-isoquinolin-2-yl)methanone Chemical compound C1=C2C(C)N(C(=O)C3=NN4C=C(Br)C=NC4=C3)CCC2=CC=C1N1CCCC1 XSDZFPJQVQSKGP-UHFFFAOYSA-N 0.000 claims 1
- GHALFGFPSJOVIR-UHFFFAOYSA-N (6-bromopyrazolo[1,5-a]pyrimidin-2-yl)-(1-methyl-8-methylsulfonyl-3,4-dihydro-1h-isoquinolin-2-yl)methanone Chemical compound C1=C2N=CC(Br)=CN2N=C1C(=O)N1C(C)C2=C(S(C)(=O)=O)C=CC=C2CC1 GHALFGFPSJOVIR-UHFFFAOYSA-N 0.000 claims 1
- RUJGTCJXFRAFRT-UHFFFAOYSA-N (6-bromopyrazolo[1,5-a]pyrimidin-2-yl)-(1-methyl-8-morpholin-4-yl-3,4-dihydro-1h-isoquinolin-2-yl)methanone Chemical compound C=12C(C)N(C(=O)C3=NN4C=C(Br)C=NC4=C3)CCC2=CC=CC=1N1CCOCC1 RUJGTCJXFRAFRT-UHFFFAOYSA-N 0.000 claims 1
- CZOGLHAUIAHPRN-UHFFFAOYSA-N (6-bromopyrazolo[1,5-a]pyrimidin-2-yl)-(1-methyl-8-nitro-3,4-dihydro-1h-isoquinolin-2-yl)methanone Chemical compound C1=C2N=CC(Br)=CN2N=C1C(=O)N1C(C)C2=C([N+]([O-])=O)C=CC=C2CC1 CZOGLHAUIAHPRN-UHFFFAOYSA-N 0.000 claims 1
- FGRHNTPOPJAZEZ-UHFFFAOYSA-N (6-bromopyrazolo[1,5-a]pyrimidin-2-yl)-(1-propan-2-yl-3,4-dihydro-1h-isoquinolin-2-yl)methanone Chemical compound C1=C2N=CC(Br)=CN2N=C1C(=O)N1C(C(C)C)C2=CC=CC=C2CC1 FGRHNTPOPJAZEZ-UHFFFAOYSA-N 0.000 claims 1
- CQVNNCLUPBWTRL-UHFFFAOYSA-N (6-bromopyrazolo[1,5-a]pyrimidin-2-yl)-(2,6-dimethyl-8,9-dihydro-6h-[1,3]oxazolo[4,5-f]isoquinolin-7-yl)methanone Chemical compound C1=C2N=CC(Br)=CN2N=C1C(=O)N1C(C)C(C=CC2=C3N=C(C)O2)=C3CC1 CQVNNCLUPBWTRL-UHFFFAOYSA-N 0.000 claims 1
- ASNRLBJYFIZEJO-UHFFFAOYSA-N (6-bromopyrazolo[1,5-a]pyrimidin-2-yl)-(2,6-dimethyl-8,9-dihydro-6h-[1,3]thiazolo[4,5-f]isoquinolin-7-yl)methanone Chemical compound C1=C2N=CC(Br)=CN2N=C1C(=O)N1C(C)C(C=CC2=C3N=C(C)S2)=C3CC1 ASNRLBJYFIZEJO-UHFFFAOYSA-N 0.000 claims 1
- YXZGJHCOMMYPIM-UHFFFAOYSA-N (6-bromopyrazolo[1,5-a]pyrimidin-2-yl)-(3-methyl-3,4-dihydro-1h-isoquinolin-2-yl)methanone Chemical compound C1=C2N=CC(Br)=CN2N=C1C(=O)N1CC2=CC=CC=C2CC1C YXZGJHCOMMYPIM-UHFFFAOYSA-N 0.000 claims 1
- XCVWTGZRBHSQGS-UHFFFAOYSA-N (6-bromopyrazolo[1,5-a]pyrimidin-2-yl)-(4-methyl-2,4-dihydro-1h-3,7-phenanthrolin-3-yl)methanone Chemical compound C1=C2N=CC(Br)=CN2N=C1C(=O)N1C(C)C(C=CC=2C3=CC=CN=2)=C3CC1 XCVWTGZRBHSQGS-UHFFFAOYSA-N 0.000 claims 1
- QFOSVWHPQUOGHG-UHFFFAOYSA-N (6-bromopyrazolo[1,5-a]pyrimidin-2-yl)-(5-methoxy-1-methyl-3,4-dihydro-1h-isoquinolin-2-yl)methanone Chemical compound C1=C2N=CC(Br)=CN2N=C1C(=O)N1C(C)C(C=CC=C2OC)=C2CC1 QFOSVWHPQUOGHG-UHFFFAOYSA-N 0.000 claims 1
- UCYWVYJFSMEGPJ-UHFFFAOYSA-N (6-bromopyrazolo[1,5-a]pyrimidin-2-yl)-(5-morpholin-4-yl-3,4-dihydro-1h-isoquinolin-2-yl)methanone Chemical compound N=1N2C=C(Br)C=NC2=CC=1C(=O)N(C1)CCC2=C1C=CC=C2N1CCOCC1 UCYWVYJFSMEGPJ-UHFFFAOYSA-N 0.000 claims 1
- ARGGVEUPCTWNTG-UHFFFAOYSA-N (6-bromopyrazolo[1,5-a]pyrimidin-2-yl)-(5-nitro-3,4-dihydro-1h-isoquinolin-2-yl)methanone Chemical compound C1=C2N=CC(Br)=CN2N=C1C(=O)N1CC(C=CC=C2[N+](=O)[O-])=C2CC1 ARGGVEUPCTWNTG-UHFFFAOYSA-N 0.000 claims 1
- BFYHPOMUTUNARW-UHFFFAOYSA-N (6-bromopyrazolo[1,5-a]pyrimidin-2-yl)-(5-pyridin-2-yl-3,4-dihydro-1h-isoquinolin-2-yl)methanone Chemical compound N=1N2C=C(Br)C=NC2=CC=1C(=O)N(C1)CCC2=C1C=CC=C2C1=CC=CC=N1 BFYHPOMUTUNARW-UHFFFAOYSA-N 0.000 claims 1
- NNEQIULUUYIGCB-UHFFFAOYSA-N (6-bromopyrazolo[1,5-a]pyrimidin-2-yl)-(6,7-dibromo-1-methyl-3,4-dihydro-1h-isoquinolin-2-yl)methanone Chemical compound C1=C2N=CC(Br)=CN2N=C1C(=O)N1C(C)C2=CC(Br)=C(Br)C=C2CC1 NNEQIULUUYIGCB-UHFFFAOYSA-N 0.000 claims 1
- MZYBVVCZOYMUAJ-UHFFFAOYSA-N (6-bromopyrazolo[1,5-a]pyrimidin-2-yl)-(6,7-dichloro-1-methyl-3,4-dihydro-1h-isoquinolin-2-yl)methanone Chemical compound C1=C2N=CC(Br)=CN2N=C1C(=O)N1C(C)C2=CC(Cl)=C(Cl)C=C2CC1 MZYBVVCZOYMUAJ-UHFFFAOYSA-N 0.000 claims 1
- DPCHAHKMTNPMMU-UHFFFAOYSA-N (6-bromopyrazolo[1,5-a]pyrimidin-2-yl)-(6,7-difluoro-1-methyl-3,4-dihydro-1h-isoquinolin-2-yl)methanone Chemical compound C1=C2N=CC(Br)=CN2N=C1C(=O)N1C(C)C2=CC(F)=C(F)C=C2CC1 DPCHAHKMTNPMMU-UHFFFAOYSA-N 0.000 claims 1
- SGGKCVNSQWGSET-UHFFFAOYSA-N (6-bromopyrazolo[1,5-a]pyrimidin-2-yl)-(6,7-dimethoxy-1-methyl-3,4-dihydro-1h-isoquinolin-2-yl)methanone Chemical compound C1=C2N=CC(Br)=CN2N=C1C(=O)N1CCC(C=C(C(=C2)OC)OC)=C2C1C SGGKCVNSQWGSET-UHFFFAOYSA-N 0.000 claims 1
- KCKCDESVLKTAJL-UHFFFAOYSA-N (6-bromopyrazolo[1,5-a]pyrimidin-2-yl)-(6,7-dimethoxy-3,3-dimethyl-1,4-dihydroisoquinolin-2-yl)methanone Chemical compound C1=C2N=CC(Br)=CN2N=C1C(=O)N1CC(C=C(C(=C2)OC)OC)=C2CC1(C)C KCKCDESVLKTAJL-UHFFFAOYSA-N 0.000 claims 1
- OLIUOPXMDNFPBO-UHFFFAOYSA-N (6-bromopyrazolo[1,5-a]pyrimidin-2-yl)-(6,7-dimethoxy-3-methyl-3,4-dihydro-1h-isoquinolin-2-yl)methanone Chemical compound C1=C2N=CC(Br)=CN2N=C1C(=O)N1C(C)CC(C=C(C(=C2)OC)OC)=C2C1 OLIUOPXMDNFPBO-UHFFFAOYSA-N 0.000 claims 1
- CJGYLYJGOQBXNU-UHFFFAOYSA-N (6-bromopyrazolo[1,5-a]pyrimidin-2-yl)-(6-hydroxy-7-methoxy-1-methyl-3,4-dihydro-1h-isoquinolin-2-yl)methanone Chemical compound C1=C2N=CC(Br)=CN2N=C1C(=O)N1C(C)C(C=C(C(=C2)O)OC)=C2CC1 CJGYLYJGOQBXNU-UHFFFAOYSA-N 0.000 claims 1
- IETUNBKSOAQQMB-UHFFFAOYSA-N (6-bromopyrazolo[1,5-a]pyrimidin-2-yl)-(6-methoxy-1-methyl-3,4-dihydro-1h-isoquinolin-2-yl)methanone Chemical compound C1=C2N=CC(Br)=CN2N=C1C(=O)N1C(C)C2=CC=C(OC)C=C2CC1 IETUNBKSOAQQMB-UHFFFAOYSA-N 0.000 claims 1
- RDHMNZKFRBAQBH-UHFFFAOYSA-N (6-bromopyrazolo[1,5-a]pyrimidin-2-yl)-(6-methyl-8,9-dihydro-6h-[1,3]dioxolo[4,5-f]isoquinolin-7-yl)methanone Chemical compound C1=C2N=CC(Br)=CN2N=C1C(=O)N1C(C)C2=CC=C3OCOC3=C2CC1 RDHMNZKFRBAQBH-UHFFFAOYSA-N 0.000 claims 1
- UUTRSGBDIYMXTL-UHFFFAOYSA-N (6-bromopyrazolo[1,5-a]pyrimidin-2-yl)-(6-morpholin-4-yl-3,4-dihydro-1h-isoquinolin-2-yl)methanone Chemical compound N=1N2C=C(Br)C=NC2=CC=1C(=O)N(CC1=CC=2)CCC1=CC=2N1CCOCC1 UUTRSGBDIYMXTL-UHFFFAOYSA-N 0.000 claims 1
- TWFOLWHERAQUFK-UHFFFAOYSA-N (6-bromopyrazolo[1,5-a]pyrimidin-2-yl)-(6-pyridin-2-yl-3,4-dihydro-1h-isoquinolin-2-yl)methanone Chemical compound N=1N2C=C(Br)C=NC2=CC=1C(=O)N(CC1=CC=2)CCC1=CC=2C1=CC=CC=N1 TWFOLWHERAQUFK-UHFFFAOYSA-N 0.000 claims 1
- OKJSKRKTCJBVJR-UHFFFAOYSA-N (6-bromopyrazolo[1,5-a]pyrimidin-2-yl)-(6-pyridin-4-yl-3,4-dihydro-1h-isoquinolin-2-yl)methanone Chemical compound N=1N2C=C(Br)C=NC2=CC=1C(=O)N(CC1=CC=2)CCC1=CC=2C1=CC=NC=C1 OKJSKRKTCJBVJR-UHFFFAOYSA-N 0.000 claims 1
- AVXSAVODCRGFCO-UHFFFAOYSA-N (6-bromopyrazolo[1,5-a]pyrimidin-2-yl)-(7-chloro-1-methyl-3,4-dihydro-1h-isoquinolin-2-yl)methanone Chemical compound C1=C2N=CC(Br)=CN2N=C1C(=O)N1C(C)C2=CC(Cl)=CC=C2CC1 AVXSAVODCRGFCO-UHFFFAOYSA-N 0.000 claims 1
- JNUYLYXRCMVIRM-UHFFFAOYSA-N (6-bromopyrazolo[1,5-a]pyrimidin-2-yl)-(7-methyl-3,7,9,10-tetrahydro-2h-[1,4]dioxino[2,3-f]isoquinolin-8-yl)methanone Chemical compound C1=C2N=CC(Br)=CN2N=C1C(=O)N1C(C)C(C=CC2=C3OCCO2)=C3CC1 JNUYLYXRCMVIRM-UHFFFAOYSA-N 0.000 claims 1
- OTNMSWUWTOJULX-UHFFFAOYSA-N (6-bromopyrazolo[1,5-a]pyrimidin-2-yl)-(7-morpholin-4-yl-3,4-dihydro-1h-isoquinolin-2-yl)methanone Chemical compound N=1N2C=C(Br)C=NC2=CC=1C(=O)N(CC1=C2)CCC1=CC=C2N1CCOCC1 OTNMSWUWTOJULX-UHFFFAOYSA-N 0.000 claims 1
- VRPJKTODYGSPRN-UHFFFAOYSA-N (6-bromopyrazolo[1,5-a]pyrimidin-2-yl)-(7-pyridin-4-yl-3,4-dihydro-1h-isoquinolin-2-yl)methanone Chemical compound N=1N2C=C(Br)C=NC2=CC=1C(=O)N(CC1=C2)CCC1=CC=C2C1=CC=NC=C1 VRPJKTODYGSPRN-UHFFFAOYSA-N 0.000 claims 1
- OONJTFIMQTVFKJ-UHFFFAOYSA-N (6-bromopyrazolo[1,5-a]pyrimidin-2-yl)-(8-methyl-6,8-dihydro-5h-pyrido[3,4-d]pyrimidin-7-yl)methanone Chemical compound C1=C2N=CC(Br)=CN2N=C1C(=O)N1C(C)C2=NC=NC=C2CC1 OONJTFIMQTVFKJ-UHFFFAOYSA-N 0.000 claims 1
- CQGXCROMGRMILW-UHFFFAOYSA-N (6-bromopyrazolo[1,5-a]pyrimidin-2-yl)-(8-morpholin-4-yl-3,4-dihydro-1h-isoquinolin-2-yl)methanone Chemical compound N=1N2C=C(Br)C=NC2=CC=1C(=O)N(CC1=2)CCC1=CC=CC=2N1CCOCC1 CQGXCROMGRMILW-UHFFFAOYSA-N 0.000 claims 1
- TUYZYSNXXSTKQX-LLVKDONJSA-N (6-bromopyrazolo[1,5-a]pyrimidin-2-yl)-[(1r)-1-methyl-3,4-dihydro-1h-isoquinolin-2-yl]methanone Chemical compound C1=C2N=CC(Br)=CN2N=C1C(=O)N1[C@H](C)C2=CC=CC=C2CC1 TUYZYSNXXSTKQX-LLVKDONJSA-N 0.000 claims 1
- TUYZYSNXXSTKQX-NSHDSACASA-N (6-bromopyrazolo[1,5-a]pyrimidin-2-yl)-[(1s)-1-methyl-3,4-dihydro-1h-isoquinolin-2-yl]methanone Chemical compound C1=C2N=CC(Br)=CN2N=C1C(=O)N1[C@@H](C)C2=CC=CC=C2CC1 TUYZYSNXXSTKQX-NSHDSACASA-N 0.000 claims 1
- HYCHWLDNCBMBGV-UHFFFAOYSA-N (6-bromopyrazolo[1,5-a]pyrimidin-2-yl)-[1-(trifluoromethyl)-3,4-dihydro-1h-isoquinolin-2-yl]methanone Chemical compound C1=C2N=CC(Br)=CN2N=C1C(=O)N1C(C(F)(F)F)C2=CC=CC=C2CC1 HYCHWLDNCBMBGV-UHFFFAOYSA-N 0.000 claims 1
- YTYWEOJAUITSHY-UHFFFAOYSA-N (6-bromopyrazolo[1,5-a]pyrimidin-2-yl)-[1-methyl-5-(1-methylpyrazol-4-yl)-3,4-dihydro-1h-isoquinolin-2-yl]methanone Chemical compound CC1N(C(=O)C2=NN3C=C(Br)C=NC3=C2)CCC2=C1C=CC=C2C=1C=NN(C)C=1 YTYWEOJAUITSHY-UHFFFAOYSA-N 0.000 claims 1
- AIEGFMKBKWMTAD-UHFFFAOYSA-N (6-bromopyrazolo[1,5-a]pyrimidin-2-yl)-[1-methyl-5-(1h-pyrazol-4-yl)-3,4-dihydro-1h-isoquinolin-2-yl]methanone Chemical compound CC1N(C(=O)C2=NN3C=C(Br)C=NC3=C2)CCC2=C1C=CC=C2C=1C=NNC=1 AIEGFMKBKWMTAD-UHFFFAOYSA-N 0.000 claims 1
- BTLUVODWTPAELP-UHFFFAOYSA-N (6-bromopyrazolo[1,5-a]pyrimidin-2-yl)-[1-methyl-5-(2h-pyrimidin-1-yl)-3,4-dihydro-1h-isoquinolin-2-yl]methanone Chemical compound CC1N(C(=O)C2=NN3C=C(Br)C=NC3=C2)CCC2=C1C=CC=C2N1CN=CC=C1 BTLUVODWTPAELP-UHFFFAOYSA-N 0.000 claims 1
- XUKXPMOJJHHMEP-UHFFFAOYSA-N (6-bromopyrazolo[1,5-a]pyrimidin-2-yl)-[1-methyl-5-(2h-tetrazol-5-yl)-3,4-dihydro-1h-isoquinolin-2-yl]methanone Chemical compound CC1N(C(=O)C2=NN3C=C(Br)C=NC3=C2)CCC2=C1C=CC=C2C=1N=NNN=1 XUKXPMOJJHHMEP-UHFFFAOYSA-N 0.000 claims 1
- UXHOVVNJXCMISK-UHFFFAOYSA-N (6-bromopyrazolo[1,5-a]pyrimidin-2-yl)-[1-methyl-5-(5-methyl-1h-pyrazol-4-yl)-3,4-dihydro-1h-isoquinolin-2-yl]methanone Chemical compound CC1N(C(=O)C2=NN3C=C(Br)C=NC3=C2)CCC2=C1C=CC=C2C1=CNN=C1C UXHOVVNJXCMISK-UHFFFAOYSA-N 0.000 claims 1
- REYCJOQLRWWRGX-UHFFFAOYSA-N (6-bromopyrazolo[1,5-a]pyrimidin-2-yl)-[1-methyl-5-(5-methylfuran-2-yl)-3,4-dihydro-1h-isoquinolin-2-yl]methanone Chemical compound CC1N(C(=O)C2=NN3C=C(Br)C=NC3=C2)CCC2=C1C=CC=C2C1=CC=C(C)O1 REYCJOQLRWWRGX-UHFFFAOYSA-N 0.000 claims 1
- XAJCFXAHWFWSMH-UHFFFAOYSA-N (6-bromopyrazolo[1,5-a]pyrimidin-2-yl)-[1-methyl-5-(trifluoromethyl)-3,4-dihydro-1h-isoquinolin-2-yl]methanone Chemical compound C1=C2N=CC(Br)=CN2N=C1C(=O)N1C(C)C(C=CC=C2C(F)(F)F)=C2CC1 XAJCFXAHWFWSMH-UHFFFAOYSA-N 0.000 claims 1
- FMOMVGQCUIJQCN-UHFFFAOYSA-N (6-bromopyrazolo[1,5-a]pyrimidin-2-yl)-[1-methyl-6-(1-methylpyrazol-4-yl)-3,4-dihydro-1h-isoquinolin-2-yl]methanone Chemical compound C=1C=C2C(C)N(C(=O)C3=NN4C=C(Br)C=NC4=C3)CCC2=CC=1C=1C=NN(C)C=1 FMOMVGQCUIJQCN-UHFFFAOYSA-N 0.000 claims 1
- DZMBPPDCFQTHCI-UHFFFAOYSA-N (6-bromopyrazolo[1,5-a]pyrimidin-2-yl)-[1-methyl-6-(1h-pyrazol-4-yl)-3,4-dihydro-1h-isoquinolin-2-yl]methanone Chemical compound C=1C=C2C(C)N(C(=O)C3=NN4C=C(Br)C=NC4=C3)CCC2=CC=1C=1C=NNC=1 DZMBPPDCFQTHCI-UHFFFAOYSA-N 0.000 claims 1
- ASPBYGYTKPQSAR-UHFFFAOYSA-N (6-bromopyrazolo[1,5-a]pyrimidin-2-yl)-[1-methyl-6-(2h-tetrazol-5-yl)-3,4-dihydro-1h-isoquinolin-2-yl]methanone Chemical compound C=1C=C2C(C)N(C(=O)C3=NN4C=C(Br)C=NC4=C3)CCC2=CC=1C=1N=NNN=1 ASPBYGYTKPQSAR-UHFFFAOYSA-N 0.000 claims 1
- YYJSDJWNOCSHDC-UHFFFAOYSA-N (6-bromopyrazolo[1,5-a]pyrimidin-2-yl)-[1-methyl-6-(5-methyl-1h-pyrazol-4-yl)-3,4-dihydro-1h-isoquinolin-2-yl]methanone Chemical compound C=1C=C2C(C)N(C(=O)C3=NN4C=C(Br)C=NC4=C3)CCC2=CC=1C1=CNN=C1C YYJSDJWNOCSHDC-UHFFFAOYSA-N 0.000 claims 1
- YORGMSUUGSAZIV-UHFFFAOYSA-N (6-bromopyrazolo[1,5-a]pyrimidin-2-yl)-[1-methyl-6-(5-methylfuran-2-yl)-3,4-dihydro-1h-isoquinolin-2-yl]methanone Chemical compound C=1C=C2C(C)N(C(=O)C3=NN4C=C(Br)C=NC4=C3)CCC2=CC=1C1=CC=C(C)O1 YORGMSUUGSAZIV-UHFFFAOYSA-N 0.000 claims 1
- WQOXNZAXJFWKJI-UHFFFAOYSA-N (6-bromopyrazolo[1,5-a]pyrimidin-2-yl)-[1-methyl-7-(1-methylpyrazol-4-yl)-3,4-dihydro-1h-isoquinolin-2-yl]methanone Chemical compound C1=C2C(C)N(C(=O)C3=NN4C=C(Br)C=NC4=C3)CCC2=CC=C1C=1C=NN(C)C=1 WQOXNZAXJFWKJI-UHFFFAOYSA-N 0.000 claims 1
- DIGZYAXATYSXHR-UHFFFAOYSA-N (6-bromopyrazolo[1,5-a]pyrimidin-2-yl)-[1-methyl-7-(1h-pyrazol-4-yl)-3,4-dihydro-1h-isoquinolin-2-yl]methanone Chemical compound C1=C2C(C)N(C(=O)C3=NN4C=C(Br)C=NC4=C3)CCC2=CC=C1C=1C=NNC=1 DIGZYAXATYSXHR-UHFFFAOYSA-N 0.000 claims 1
- FJTJJUBLFJUPRI-UHFFFAOYSA-N (6-bromopyrazolo[1,5-a]pyrimidin-2-yl)-[1-methyl-7-(2h-tetrazol-5-yl)-3,4-dihydro-1h-isoquinolin-2-yl]methanone Chemical compound C1=C2C(C)N(C(=O)C3=NN4C=C(Br)C=NC4=C3)CCC2=CC=C1C=1N=NNN=1 FJTJJUBLFJUPRI-UHFFFAOYSA-N 0.000 claims 1
- MFDWAVSWUXMOAM-UHFFFAOYSA-N (6-bromopyrazolo[1,5-a]pyrimidin-2-yl)-[1-methyl-7-(5-methyl-1h-pyrazol-4-yl)-3,4-dihydro-1h-isoquinolin-2-yl]methanone Chemical compound C1=C2C(C)N(C(=O)C3=NN4C=C(Br)C=NC4=C3)CCC2=CC=C1C1=CNN=C1C MFDWAVSWUXMOAM-UHFFFAOYSA-N 0.000 claims 1
- SOFCLCKQYGGOAA-UHFFFAOYSA-N (6-bromopyrazolo[1,5-a]pyrimidin-2-yl)-[1-methyl-8-(1-methylpyrazol-4-yl)-3,4-dihydro-1h-isoquinolin-2-yl]methanone Chemical compound C=12C(C)N(C(=O)C3=NN4C=C(Br)C=NC4=C3)CCC2=CC=CC=1C=1C=NN(C)C=1 SOFCLCKQYGGOAA-UHFFFAOYSA-N 0.000 claims 1
- DTGDAUXBELPGJW-UHFFFAOYSA-N (6-bromopyrazolo[1,5-a]pyrimidin-2-yl)-[1-methyl-8-(1h-pyrazol-4-yl)-3,4-dihydro-1h-isoquinolin-2-yl]methanone Chemical compound C=12C(C)N(C(=O)C3=NN4C=C(Br)C=NC4=C3)CCC2=CC=CC=1C=1C=NNC=1 DTGDAUXBELPGJW-UHFFFAOYSA-N 0.000 claims 1
- FEQGRPNEVMDHEO-UHFFFAOYSA-N (6-bromopyrazolo[1,5-a]pyrimidin-2-yl)-[1-methyl-8-(2h-tetrazol-5-yl)-3,4-dihydro-1h-isoquinolin-2-yl]methanone Chemical compound C=12C(C)N(C(=O)C3=NN4C=C(Br)C=NC4=C3)CCC2=CC=CC=1C=1N=NNN=1 FEQGRPNEVMDHEO-UHFFFAOYSA-N 0.000 claims 1
- BXYPZZWUMIGCAH-UHFFFAOYSA-N (6-bromopyrazolo[1,5-a]pyrimidin-2-yl)-[5-(2-methoxypyridin-3-yl)-1-methyl-3,4-dihydro-1h-isoquinolin-2-yl]methanone Chemical compound COC1=NC=CC=C1C1=CC=CC2=C1CCN(C(=O)C1=NN3C=C(Br)C=NC3=C1)C2C BXYPZZWUMIGCAH-UHFFFAOYSA-N 0.000 claims 1
- BHDCOTFCPRGKHE-UHFFFAOYSA-N (6-bromopyrazolo[1,5-a]pyrimidin-2-yl)-[5-(3,5-dimethyl-1,2-oxazol-4-yl)-1-methyl-3,4-dihydro-1h-isoquinolin-2-yl]methanone Chemical compound CC1N(C(=O)C2=NN3C=C(Br)C=NC3=C2)CCC2=C1C=CC=C2C=1C(C)=NOC=1C BHDCOTFCPRGKHE-UHFFFAOYSA-N 0.000 claims 1
- PDNRFFBZCNVPGJ-UHFFFAOYSA-N (6-bromopyrazolo[1,5-a]pyrimidin-2-yl)-[5-(6-fluoropyridin-3-yl)-1-methyl-3,4-dihydro-1h-isoquinolin-2-yl]methanone Chemical compound CC1N(C(=O)C2=NN3C=C(Br)C=NC3=C2)CCC2=C1C=CC=C2C1=CC=C(F)N=C1 PDNRFFBZCNVPGJ-UHFFFAOYSA-N 0.000 claims 1
- WPGRDLGRBCSNHH-UHFFFAOYSA-N (6-bromopyrazolo[1,5-a]pyrimidin-2-yl)-[5-(6-methoxypyridin-3-yl)-1-methyl-3,4-dihydro-1h-isoquinolin-2-yl]methanone Chemical compound C1=NC(OC)=CC=C1C1=CC=CC2=C1CCN(C(=O)C1=NN3C=C(Br)C=NC3=C1)C2C WPGRDLGRBCSNHH-UHFFFAOYSA-N 0.000 claims 1
- APTLWZXIQKUUDU-UHFFFAOYSA-N (6-bromopyrazolo[1,5-a]pyrimidin-2-yl)-[5-(diethylamino)-1-methyl-3,4-dihydro-1h-isoquinolin-2-yl]methanone Chemical compound C1=C2N=CC(Br)=CN2N=C1C(=O)N1C(C)C(C=CC=C2N(CC)CC)=C2CC1 APTLWZXIQKUUDU-UHFFFAOYSA-N 0.000 claims 1
- SZUXCHHJEPOWMT-UHFFFAOYSA-N (6-bromopyrazolo[1,5-a]pyrimidin-2-yl)-[5-(furan-3-yl)-1-methyl-3,4-dihydro-1h-isoquinolin-2-yl]methanone Chemical compound CC1N(C(=O)C2=NN3C=C(Br)C=NC3=C2)CCC2=C1C=CC=C2C=1C=COC=1 SZUXCHHJEPOWMT-UHFFFAOYSA-N 0.000 claims 1
- ROXHEZFMKWOPRP-UHFFFAOYSA-N (6-bromopyrazolo[1,5-a]pyrimidin-2-yl)-[6-(2,4-dimethoxypyrimidin-5-yl)-1-methyl-3,4-dihydro-1h-isoquinolin-2-yl]methanone Chemical compound COC1=NC(OC)=NC=C1C1=CC=C(C(C)N(CC2)C(=O)C3=NN4C=C(Br)C=NC4=C3)C2=C1 ROXHEZFMKWOPRP-UHFFFAOYSA-N 0.000 claims 1
- BDHJPLSJWONSIN-UHFFFAOYSA-N (6-bromopyrazolo[1,5-a]pyrimidin-2-yl)-[6-(2,6-dimethoxypyridin-3-yl)-1-methyl-3,4-dihydro-1h-isoquinolin-2-yl]methanone Chemical compound COC1=NC(OC)=CC=C1C1=CC=C(C(C)N(CC2)C(=O)C3=NN4C=C(Br)C=NC4=C3)C2=C1 BDHJPLSJWONSIN-UHFFFAOYSA-N 0.000 claims 1
- XRUPRFFVQALWFA-UHFFFAOYSA-N (6-bromopyrazolo[1,5-a]pyrimidin-2-yl)-[6-(2-fluoropyridin-3-yl)-1-methyl-3,4-dihydro-1h-isoquinolin-2-yl]methanone Chemical compound C=1C=C2C(C)N(C(=O)C3=NN4C=C(Br)C=NC4=C3)CCC2=CC=1C1=CC=CN=C1F XRUPRFFVQALWFA-UHFFFAOYSA-N 0.000 claims 1
- LMFXWLNQFLAFLP-UHFFFAOYSA-N (6-bromopyrazolo[1,5-a]pyrimidin-2-yl)-[6-(2-methoxypyridin-3-yl)-1-methyl-3,4-dihydro-1h-isoquinolin-2-yl]methanone Chemical compound COC1=NC=CC=C1C1=CC=C(C(C)N(CC2)C(=O)C3=NN4C=C(Br)C=NC4=C3)C2=C1 LMFXWLNQFLAFLP-UHFFFAOYSA-N 0.000 claims 1
- DCKWSLWMEKKPRY-UHFFFAOYSA-N (6-bromopyrazolo[1,5-a]pyrimidin-2-yl)-[6-(3,5-dimethyl-1,2-oxazol-4-yl)-1-methyl-3,4-dihydro-1h-isoquinolin-2-yl]methanone Chemical compound C=1C=C2C(C)N(C(=O)C3=NN4C=C(Br)C=NC4=C3)CCC2=CC=1C=1C(C)=NOC=1C DCKWSLWMEKKPRY-UHFFFAOYSA-N 0.000 claims 1
- SOCIFAVWRCAEDK-UHFFFAOYSA-N (6-bromopyrazolo[1,5-a]pyrimidin-2-yl)-[6-(6-fluoropyridin-3-yl)-1-methyl-3,4-dihydro-1h-isoquinolin-2-yl]methanone Chemical compound C=1C=C2C(C)N(C(=O)C3=NN4C=C(Br)C=NC4=C3)CCC2=CC=1C1=CC=C(F)N=C1 SOCIFAVWRCAEDK-UHFFFAOYSA-N 0.000 claims 1
- YHQHDGXVTYCPRJ-UHFFFAOYSA-N (6-bromopyrazolo[1,5-a]pyrimidin-2-yl)-[6-(diethylamino)-1-methyl-3,4-dihydro-1h-isoquinolin-2-yl]methanone Chemical compound C1=C2N=CC(Br)=CN2N=C1C(=O)N1C(C)C2=CC=C(N(CC)CC)C=C2CC1 YHQHDGXVTYCPRJ-UHFFFAOYSA-N 0.000 claims 1
- QDHQDTWGCMZUDK-UHFFFAOYSA-N (6-bromopyrazolo[1,5-a]pyrimidin-2-yl)-[6-(furan-3-yl)-1-methyl-3,4-dihydro-1h-isoquinolin-2-yl]methanone Chemical compound C=1C=C2C(C)N(C(=O)C3=NN4C=C(Br)C=NC4=C3)CCC2=CC=1C=1C=COC=1 QDHQDTWGCMZUDK-UHFFFAOYSA-N 0.000 claims 1
- IVGHLSDHJWONKH-UHFFFAOYSA-N (6-bromopyrazolo[1,5-a]pyrimidin-2-yl)-[7-(2,4-dimethoxypyrimidin-5-yl)-1-methyl-3,4-dihydro-1h-isoquinolin-2-yl]methanone Chemical compound COC1=NC(OC)=NC=C1C1=CC=C(CCN(C2C)C(=O)C3=NN4C=C(Br)C=NC4=C3)C2=C1 IVGHLSDHJWONKH-UHFFFAOYSA-N 0.000 claims 1
- NKVQDZCLWMNMDC-UHFFFAOYSA-N (6-bromopyrazolo[1,5-a]pyrimidin-2-yl)-[7-(2-fluoropyridin-3-yl)-1-methyl-3,4-dihydro-1h-isoquinolin-2-yl]methanone Chemical compound C1=C2C(C)N(C(=O)C3=NN4C=C(Br)C=NC4=C3)CCC2=CC=C1C1=CC=CN=C1F NKVQDZCLWMNMDC-UHFFFAOYSA-N 0.000 claims 1
- UGEHKZQFJTVPTC-UHFFFAOYSA-N (6-bromopyrazolo[1,5-a]pyrimidin-2-yl)-[7-(3,5-dimethyl-1,2-oxazol-4-yl)-1-methyl-3,4-dihydro-1h-isoquinolin-2-yl]methanone Chemical compound C1=C2C(C)N(C(=O)C3=NN4C=C(Br)C=NC4=C3)CCC2=CC=C1C=1C(C)=NOC=1C UGEHKZQFJTVPTC-UHFFFAOYSA-N 0.000 claims 1
- NCNYBNOSDBOVNE-UHFFFAOYSA-N (6-bromopyrazolo[1,5-a]pyrimidin-2-yl)-[7-(diethylamino)-1-methyl-3,4-dihydro-1h-isoquinolin-2-yl]methanone Chemical compound C1=C2N=CC(Br)=CN2N=C1C(=O)N1CCC2=CC=C(N(CC)CC)C=C2C1C NCNYBNOSDBOVNE-UHFFFAOYSA-N 0.000 claims 1
- ZQDCPHYFQPINAW-UHFFFAOYSA-N (6-bromopyrazolo[1,5-a]pyrimidin-2-yl)-[7-(furan-3-yl)-1-methyl-3,4-dihydro-1h-isoquinolin-2-yl]methanone Chemical compound C1=C2C(C)N(C(=O)C3=NN4C=C(Br)C=NC4=C3)CCC2=CC=C1C=1C=COC=1 ZQDCPHYFQPINAW-UHFFFAOYSA-N 0.000 claims 1
- HRXUFMHMPOBSBK-UHFFFAOYSA-N (6-bromopyrazolo[1,5-a]pyrimidin-2-yl)-[8-(3,5-dimethyl-1,2-oxazol-4-yl)-1-methyl-3,4-dihydro-1h-isoquinolin-2-yl]methanone Chemical compound C=12C(C)N(C(=O)C3=NN4C=C(Br)C=NC4=C3)CCC2=CC=CC=1C=1C(C)=NOC=1C HRXUFMHMPOBSBK-UHFFFAOYSA-N 0.000 claims 1
- LFFCCCHVCVSMJW-UHFFFAOYSA-N (6-bromopyrazolo[1,5-a]pyrimidin-2-yl)-[8-(diethylamino)-1-methyl-3,4-dihydro-1h-isoquinolin-2-yl]methanone Chemical compound C1=C2N=CC(Br)=CN2N=C1C(=O)N1CCC(C=CC=C2N(CC)CC)=C2C1C LFFCCCHVCVSMJW-UHFFFAOYSA-N 0.000 claims 1
- RSBBEMBHTOQRRP-UHFFFAOYSA-N (6-bromopyrazolo[1,5-a]pyrimidin-2-yl)-[8-(furan-2-yl)-1-methyl-3,4-dihydro-1h-isoquinolin-2-yl]methanone Chemical compound C=12C(C)N(C(=O)C3=NN4C=C(Br)C=NC4=C3)CCC2=CC=CC=1C1=CC=CO1 RSBBEMBHTOQRRP-UHFFFAOYSA-N 0.000 claims 1
- BWXLGUGDXYNQJH-UHFFFAOYSA-N (6-chloropyrazolo[1,5-a]pyrimidin-2-yl)-(1-ethyl-3,4-dihydro-1h-isoquinolin-2-yl)methanone Chemical compound C1=C2N=CC(Cl)=CN2N=C1C(=O)N1C(CC)C2=CC=CC=C2CC1 BWXLGUGDXYNQJH-UHFFFAOYSA-N 0.000 claims 1
- LFCNNHHVDNTSSD-UHFFFAOYSA-N (6-chloropyrazolo[1,5-a]pyrimidin-2-yl)-(1-methyl-3,4-dihydro-1h-isoquinolin-2-yl)methanone Chemical compound C1=C2N=CC(Cl)=CN2N=C1C(=O)N1C(C)C2=CC=CC=C2CC1 LFCNNHHVDNTSSD-UHFFFAOYSA-N 0.000 claims 1
- RXKYCPCTCMXUJM-UHFFFAOYSA-N (6-chloropyrazolo[1,5-a]pyrimidin-2-yl)-(1-methyl-5-morpholin-4-yl-3,4-dihydro-1h-isoquinolin-2-yl)methanone Chemical compound CC1N(C(=O)C2=NN3C=C(Cl)C=NC3=C2)CCC2=C1C=CC=C2N1CCOCC1 RXKYCPCTCMXUJM-UHFFFAOYSA-N 0.000 claims 1
- ULQUHOGFGSFAIQ-UHFFFAOYSA-N (6-chloropyrazolo[1,5-a]pyrimidin-2-yl)-(1-methyl-5-pyridin-4-yl-3,4-dihydro-1h-isoquinolin-2-yl)methanone Chemical compound CC1N(C(=O)C2=NN3C=C(Cl)C=NC3=C2)CCC2=C1C=CC=C2C1=CC=NC=C1 ULQUHOGFGSFAIQ-UHFFFAOYSA-N 0.000 claims 1
- VZHNMCJEMZPZQQ-UHFFFAOYSA-N (6-chloropyrazolo[1,5-a]pyrimidin-2-yl)-(1-methyl-6-morpholin-4-yl-3,4-dihydro-1h-isoquinolin-2-yl)methanone Chemical compound C=1C=C2C(C)N(C(=O)C3=NN4C=C(Cl)C=NC4=C3)CCC2=CC=1N1CCOCC1 VZHNMCJEMZPZQQ-UHFFFAOYSA-N 0.000 claims 1
- IEEHFACRMHERID-UHFFFAOYSA-N (6-chloropyrazolo[1,5-a]pyrimidin-2-yl)-(1-methyl-6-pyridin-2-yl-3,4-dihydro-1h-isoquinolin-2-yl)methanone Chemical compound C=1C=C2C(C)N(C(=O)C3=NN4C=C(Cl)C=NC4=C3)CCC2=CC=1C1=CC=CC=N1 IEEHFACRMHERID-UHFFFAOYSA-N 0.000 claims 1
- HSTCWRWLXMECBM-UHFFFAOYSA-N (6-chloropyrazolo[1,5-a]pyrimidin-2-yl)-(1-methyl-6-pyridin-4-yl-3,4-dihydro-1h-isoquinolin-2-yl)methanone Chemical compound C=1C=C2C(C)N(C(=O)C3=NN4C=C(Cl)C=NC4=C3)CCC2=CC=1C1=CC=NC=C1 HSTCWRWLXMECBM-UHFFFAOYSA-N 0.000 claims 1
- HYRKUWMQQOETLC-UHFFFAOYSA-N (6-chloropyrazolo[1,5-a]pyrimidin-2-yl)-(1-methyl-7-morpholin-4-yl-3,4-dihydro-1h-isoquinolin-2-yl)methanone Chemical compound C1=C2C(C)N(C(=O)C3=NN4C=C(Cl)C=NC4=C3)CCC2=CC=C1N1CCOCC1 HYRKUWMQQOETLC-UHFFFAOYSA-N 0.000 claims 1
- ITAFPGFLORMYKT-UHFFFAOYSA-N (6-chloropyrazolo[1,5-a]pyrimidin-2-yl)-(1-methyl-7-pyridin-2-yl-3,4-dihydro-1h-isoquinolin-2-yl)methanone Chemical compound C1=C2C(C)N(C(=O)C3=NN4C=C(Cl)C=NC4=C3)CCC2=CC=C1C1=CC=CC=N1 ITAFPGFLORMYKT-UHFFFAOYSA-N 0.000 claims 1
- QSNIXTMJPWDSEK-UHFFFAOYSA-N (6-chloropyrazolo[1,5-a]pyrimidin-2-yl)-(1-methyl-7-pyrrolidin-1-yl-3,4-dihydro-1h-isoquinolin-2-yl)methanone Chemical compound C1=C2C(C)N(C(=O)C3=NN4C=C(Cl)C=NC4=C3)CCC2=CC=C1N1CCCC1 QSNIXTMJPWDSEK-UHFFFAOYSA-N 0.000 claims 1
- KXJZVKDSOPWKTO-UHFFFAOYSA-N (6-chloropyrazolo[1,5-a]pyrimidin-2-yl)-(1-methyl-8-morpholin-4-yl-3,4-dihydro-1h-isoquinolin-2-yl)methanone Chemical compound C=12C(C)N(C(=O)C3=NN4C=C(Cl)C=NC4=C3)CCC2=CC=CC=1N1CCOCC1 KXJZVKDSOPWKTO-UHFFFAOYSA-N 0.000 claims 1
- JAWAOSJJQJLZGB-UHFFFAOYSA-N (6-chloropyrazolo[1,5-a]pyrimidin-2-yl)-(1-propan-2-yl-3,4-dihydro-1h-isoquinolin-2-yl)methanone Chemical compound C1=C2N=CC(Cl)=CN2N=C1C(=O)N1C(C(C)C)C2=CC=CC=C2CC1 JAWAOSJJQJLZGB-UHFFFAOYSA-N 0.000 claims 1
- UFJHZRZMEYGZAC-UHFFFAOYSA-N (6-chloropyrazolo[1,5-a]pyrimidin-2-yl)-(3,4-dihydro-1h-isoquinolin-2-yl)methanone Chemical compound C1CC2=CC=CC=C2CN1C(=O)C1=NN(C=C(Cl)C=N2)C2=C1 UFJHZRZMEYGZAC-UHFFFAOYSA-N 0.000 claims 1
- GHWGMUDNNTUZEM-UHFFFAOYSA-N (6-chloropyrazolo[1,5-a]pyrimidin-2-yl)-(3-methyl-3,4-dihydro-1h-isoquinolin-2-yl)methanone Chemical compound C1=C2N=CC(Cl)=CN2N=C1C(=O)N1CC2=CC=CC=C2CC1C GHWGMUDNNTUZEM-UHFFFAOYSA-N 0.000 claims 1
- BJISKQCYXOQIRU-UHFFFAOYSA-N (6-chloropyrazolo[1,5-a]pyrimidin-2-yl)-(5-morpholin-4-yl-3,4-dihydro-1h-isoquinolin-2-yl)methanone Chemical compound N=1N2C=C(Cl)C=NC2=CC=1C(=O)N(C1)CCC2=C1C=CC=C2N1CCOCC1 BJISKQCYXOQIRU-UHFFFAOYSA-N 0.000 claims 1
- MYQGUZFAFUOZKK-UHFFFAOYSA-N (6-chloropyrazolo[1,5-a]pyrimidin-2-yl)-(5-nitro-3,4-dihydro-1h-isoquinolin-2-yl)methanone Chemical compound C1=C2N=CC(Cl)=CN2N=C1C(=O)N1CC(C=CC=C2[N+](=O)[O-])=C2CC1 MYQGUZFAFUOZKK-UHFFFAOYSA-N 0.000 claims 1
- JEXSNCYKIZTENM-UHFFFAOYSA-N (6-chloropyrazolo[1,5-a]pyrimidin-2-yl)-(6,7-dibromo-1-methyl-3,4-dihydro-1h-isoquinolin-2-yl)methanone Chemical compound C1=C2N=CC(Cl)=CN2N=C1C(=O)N1C(C)C2=CC(Br)=C(Br)C=C2CC1 JEXSNCYKIZTENM-UHFFFAOYSA-N 0.000 claims 1
- GYAQQDFTEKTQRT-UHFFFAOYSA-N (6-chloropyrazolo[1,5-a]pyrimidin-2-yl)-(6,7-dichloro-1-methyl-3,4-dihydro-1h-isoquinolin-2-yl)methanone Chemical compound C1=C2N=CC(Cl)=CN2N=C1C(=O)N1C(C)C2=CC(Cl)=C(Cl)C=C2CC1 GYAQQDFTEKTQRT-UHFFFAOYSA-N 0.000 claims 1
- BFERZCFVPWBLDN-UHFFFAOYSA-N (6-chloropyrazolo[1,5-a]pyrimidin-2-yl)-(6,7-difluoro-1-methyl-3,4-dihydro-1h-isoquinolin-2-yl)methanone Chemical compound C1=C2N=CC(Cl)=CN2N=C1C(=O)N1C(C)C2=CC(F)=C(F)C=C2CC1 BFERZCFVPWBLDN-UHFFFAOYSA-N 0.000 claims 1
- FBFKRWFBZORBPV-UHFFFAOYSA-N (6-chloropyrazolo[1,5-a]pyrimidin-2-yl)-(6,7-dimethoxy-1-methyl-3,4-dihydro-1h-isoquinolin-2-yl)methanone Chemical compound C1=C2N=CC(Cl)=CN2N=C1C(=O)N1CCC(C=C(C(=C2)OC)OC)=C2C1C FBFKRWFBZORBPV-UHFFFAOYSA-N 0.000 claims 1
- OIMZSGJWWCVGGW-UHFFFAOYSA-N (6-chloropyrazolo[1,5-a]pyrimidin-2-yl)-(6,7-dimethoxy-3,3-dimethyl-1,4-dihydroisoquinolin-2-yl)methanone Chemical compound C1=C2N=CC(Cl)=CN2N=C1C(=O)N1CC(C=C(C(=C2)OC)OC)=C2CC1(C)C OIMZSGJWWCVGGW-UHFFFAOYSA-N 0.000 claims 1
- PRCKQIHHWNTDMW-UHFFFAOYSA-N (6-chloropyrazolo[1,5-a]pyrimidin-2-yl)-(6,7-dimethoxy-3-methyl-3,4-dihydro-1h-isoquinolin-2-yl)methanone Chemical compound C1=C2N=CC(Cl)=CN2N=C1C(=O)N1C(C)CC(C=C(C(=C2)OC)OC)=C2C1 PRCKQIHHWNTDMW-UHFFFAOYSA-N 0.000 claims 1
- YJJCPIQSSSGYIM-UHFFFAOYSA-N (6-chloropyrazolo[1,5-a]pyrimidin-2-yl)-(6-hydroxy-7-methoxy-1-methyl-3,4-dihydro-1h-isoquinolin-2-yl)methanone Chemical compound C1=C2N=CC(Cl)=CN2N=C1C(=O)N1C(C)C(C=C(C(=C2)O)OC)=C2CC1 YJJCPIQSSSGYIM-UHFFFAOYSA-N 0.000 claims 1
- JUIDNJRRUQTDHZ-UHFFFAOYSA-N (6-chloropyrazolo[1,5-a]pyrimidin-2-yl)-(6-hydroxy-7-methoxy-3,4-dihydro-1h-isoquinolin-2-yl)methanone Chemical compound C1=C2N=CC(Cl)=CN2N=C1C(=O)N1CC(C=C(C(=C2)O)OC)=C2CC1 JUIDNJRRUQTDHZ-UHFFFAOYSA-N 0.000 claims 1
- MBBSOMCYVSFBJP-UHFFFAOYSA-N (6-chloropyrazolo[1,5-a]pyrimidin-2-yl)-(6-methoxy-1-methyl-3,4-dihydro-1h-isoquinolin-2-yl)methanone Chemical compound C1=C2N=CC(Cl)=CN2N=C1C(=O)N1C(C)C2=CC=C(OC)C=C2CC1 MBBSOMCYVSFBJP-UHFFFAOYSA-N 0.000 claims 1
- OJJXKHATUIHJLL-UHFFFAOYSA-N (6-chloropyrazolo[1,5-a]pyrimidin-2-yl)-(6-morpholin-4-yl-3,4-dihydro-1h-isoquinolin-2-yl)methanone Chemical compound N=1N2C=C(Cl)C=NC2=CC=1C(=O)N(CC1=CC=2)CCC1=CC=2N1CCOCC1 OJJXKHATUIHJLL-UHFFFAOYSA-N 0.000 claims 1
- JHSAYKRNQNCFDZ-UHFFFAOYSA-N (6-chloropyrazolo[1,5-a]pyrimidin-2-yl)-(6-pyridin-4-yl-3,4-dihydro-1h-isoquinolin-2-yl)methanone Chemical compound N=1N2C=C(Cl)C=NC2=CC=1C(=O)N(CC1=CC=2)CCC1=CC=2C1=CC=NC=C1 JHSAYKRNQNCFDZ-UHFFFAOYSA-N 0.000 claims 1
- AIIBQDVFVHIFMW-UHFFFAOYSA-N (6-chloropyrazolo[1,5-a]pyrimidin-2-yl)-(7-morpholin-4-yl-3,4-dihydro-1h-isoquinolin-2-yl)methanone Chemical compound N=1N2C=C(Cl)C=NC2=CC=1C(=O)N(CC1=C2)CCC1=CC=C2N1CCOCC1 AIIBQDVFVHIFMW-UHFFFAOYSA-N 0.000 claims 1
- YNTRFNAXKDZEEG-UHFFFAOYSA-N (6-chloropyrazolo[1,5-a]pyrimidin-2-yl)-(8-morpholin-4-yl-3,4-dihydro-1h-isoquinolin-2-yl)methanone Chemical compound N=1N2C=C(Cl)C=NC2=CC=1C(=O)N(CC1=2)CCC1=CC=CC=2N1CCOCC1 YNTRFNAXKDZEEG-UHFFFAOYSA-N 0.000 claims 1
- DLQRBCKNEVVAFK-UHFFFAOYSA-N (6-chloropyrazolo[1,5-a]pyrimidin-2-yl)-[1-(trifluoromethyl)-3,4-dihydro-1h-isoquinolin-2-yl]methanone Chemical compound C1=C2N=CC(Cl)=CN2N=C1C(=O)N1C(C(F)(F)F)C2=CC=CC=C2CC1 DLQRBCKNEVVAFK-UHFFFAOYSA-N 0.000 claims 1
- LKUORLTZFXEPCT-UHFFFAOYSA-N (6-chloropyrazolo[1,5-a]pyrimidin-2-yl)-[1-methyl-5-(trifluoromethyl)-3,4-dihydro-1h-isoquinolin-2-yl]methanone Chemical compound C1=C2N=CC(Cl)=CN2N=C1C(=O)N1C(C)C(C=CC=C2C(F)(F)F)=C2CC1 LKUORLTZFXEPCT-UHFFFAOYSA-N 0.000 claims 1
- JJPNYXJIFAFYBF-UHFFFAOYSA-N (6-chloropyrazolo[1,5-a]pyrimidin-2-yl)-[5-(2,4-dimethoxypyrimidin-5-yl)-1-methyl-3,4-dihydro-1h-isoquinolin-2-yl]methanone Chemical compound COC1=NC(OC)=NC=C1C1=CC=CC2=C1CCN(C(=O)C1=NN3C=C(Cl)C=NC3=C1)C2C JJPNYXJIFAFYBF-UHFFFAOYSA-N 0.000 claims 1
- MWBNLVWOJRWLRH-UHFFFAOYSA-N (6-chloropyrazolo[1,5-a]pyrimidin-2-yl)-[5-(2,6-dimethoxypyridin-3-yl)-1-methyl-3,4-dihydro-1h-isoquinolin-2-yl]methanone Chemical compound COC1=NC(OC)=CC=C1C1=CC=CC2=C1CCN(C(=O)C1=NN3C=C(Cl)C=NC3=C1)C2C MWBNLVWOJRWLRH-UHFFFAOYSA-N 0.000 claims 1
- OBJXGRSSJJMWSN-UHFFFAOYSA-N (6-chloropyrazolo[1,5-a]pyrimidin-2-yl)-[5-(2-methoxypyridin-3-yl)-1-methyl-3,4-dihydro-1h-isoquinolin-2-yl]methanone Chemical compound COC1=NC=CC=C1C1=CC=CC2=C1CCN(C(=O)C1=NN3C=C(Cl)C=NC3=C1)C2C OBJXGRSSJJMWSN-UHFFFAOYSA-N 0.000 claims 1
- REZWWJSFEZYKKT-UHFFFAOYSA-N (6-chloropyrazolo[1,5-a]pyrimidin-2-yl)-[5-(6-fluoropyridin-3-yl)-1-methyl-3,4-dihydro-1h-isoquinolin-2-yl]methanone Chemical compound CC1N(C(=O)C2=NN3C=C(Cl)C=NC3=C2)CCC2=C1C=CC=C2C1=CC=C(F)N=C1 REZWWJSFEZYKKT-UHFFFAOYSA-N 0.000 claims 1
- WGCAKGIGZUUHOP-UHFFFAOYSA-N (6-chloropyrazolo[1,5-a]pyrimidin-2-yl)-[5-(6-methoxypyridin-3-yl)-1-methyl-3,4-dihydro-1h-isoquinolin-2-yl]methanone Chemical compound C1=NC(OC)=CC=C1C1=CC=CC2=C1CCN(C(=O)C1=NN3C=C(Cl)C=NC3=C1)C2C WGCAKGIGZUUHOP-UHFFFAOYSA-N 0.000 claims 1
- GIXRTUKKICCHLF-UHFFFAOYSA-N (6-chloropyrazolo[1,5-a]pyrimidin-2-yl)-[6-(2,4-dimethoxypyrimidin-5-yl)-1-methyl-3,4-dihydro-1h-isoquinolin-2-yl]methanone Chemical compound COC1=NC(OC)=NC=C1C1=CC=C(C(C)N(CC2)C(=O)C3=NN4C=C(Cl)C=NC4=C3)C2=C1 GIXRTUKKICCHLF-UHFFFAOYSA-N 0.000 claims 1
- FETBDFJUIABEKI-UHFFFAOYSA-N (6-chloropyrazolo[1,5-a]pyrimidin-2-yl)-[6-(2,6-dimethoxypyridin-3-yl)-1-methyl-3,4-dihydro-1h-isoquinolin-2-yl]methanone Chemical compound COC1=NC(OC)=CC=C1C1=CC=C(C(C)N(CC2)C(=O)C3=NN4C=C(Cl)C=NC4=C3)C2=C1 FETBDFJUIABEKI-UHFFFAOYSA-N 0.000 claims 1
- VXJXLUTVDDYABZ-UHFFFAOYSA-N (6-chloropyrazolo[1,5-a]pyrimidin-2-yl)-[6-(2-fluoropyridin-3-yl)-1-methyl-3,4-dihydro-1h-isoquinolin-2-yl]methanone Chemical compound C=1C=C2C(C)N(C(=O)C3=NN4C=C(Cl)C=NC4=C3)CCC2=CC=1C1=CC=CN=C1F VXJXLUTVDDYABZ-UHFFFAOYSA-N 0.000 claims 1
- ACYSPJREEMKGFM-UHFFFAOYSA-N (6-chloropyrazolo[1,5-a]pyrimidin-2-yl)-[6-(2-methoxypyridin-3-yl)-1-methyl-3,4-dihydro-1h-isoquinolin-2-yl]methanone Chemical compound COC1=NC=CC=C1C1=CC=C(C(C)N(CC2)C(=O)C3=NN4C=C(Cl)C=NC4=C3)C2=C1 ACYSPJREEMKGFM-UHFFFAOYSA-N 0.000 claims 1
- JMNBNYBHBKLTGF-UHFFFAOYSA-N (6-chloropyrazolo[1,5-a]pyrimidin-2-yl)-[6-(6-fluoropyridin-3-yl)-1-methyl-3,4-dihydro-1h-isoquinolin-2-yl]methanone Chemical compound C=1C=C2C(C)N(C(=O)C3=NN4C=C(Cl)C=NC4=C3)CCC2=CC=1C1=CC=C(F)N=C1 JMNBNYBHBKLTGF-UHFFFAOYSA-N 0.000 claims 1
- QGGNQAOQOLVCIL-UHFFFAOYSA-N (6-chloropyrazolo[1,5-a]pyrimidin-2-yl)-[7-(2,4-dimethoxypyrimidin-5-yl)-1-methyl-3,4-dihydro-1h-isoquinolin-2-yl]methanone Chemical compound COC1=NC(OC)=NC=C1C1=CC=C(CCN(C2C)C(=O)C3=NN4C=C(Cl)C=NC4=C3)C2=C1 QGGNQAOQOLVCIL-UHFFFAOYSA-N 0.000 claims 1
- JRBPORGOQBWFFF-UHFFFAOYSA-N (6-chloropyrazolo[1,5-a]pyrimidin-2-yl)-[7-(2-methoxypyridin-3-yl)-1-methyl-3,4-dihydro-1h-isoquinolin-2-yl]methanone Chemical compound COC1=NC=CC=C1C1=CC=C(CCN(C2C)C(=O)C3=NN4C=C(Cl)C=NC4=C3)C2=C1 JRBPORGOQBWFFF-UHFFFAOYSA-N 0.000 claims 1
- CCAXCMOEKHKQMS-UHFFFAOYSA-N (6-chloropyrazolo[1,5-a]pyrimidin-2-yl)-[7-(6-methoxypyridin-3-yl)-1-methyl-3,4-dihydro-1h-isoquinolin-2-yl]methanone Chemical compound C1=NC(OC)=CC=C1C1=CC=C(CCN(C2C)C(=O)C3=NN4C=C(Cl)C=NC4=C3)C2=C1 CCAXCMOEKHKQMS-UHFFFAOYSA-N 0.000 claims 1
- UNONJQXPKUVKKL-UHFFFAOYSA-N (7-bromo-1-methyl-3,4-dihydro-1h-isoquinolin-2-yl)-(6-bromopyrazolo[1,5-a]pyrimidin-2-yl)methanone Chemical compound C1=C2N=CC(Br)=CN2N=C1C(=O)N1C(C)C2=CC(Br)=CC=C2CC1 UNONJQXPKUVKKL-UHFFFAOYSA-N 0.000 claims 1
- IIEMCFBTMREQJC-UHFFFAOYSA-N (7-bromo-1-methyl-3,4-dihydro-1h-isoquinolin-2-yl)-(6-chloropyrazolo[1,5-a]pyrimidin-2-yl)methanone Chemical compound C1=C2N=CC(Cl)=CN2N=C1C(=O)N1C(C)C2=CC(Br)=CC=C2CC1 IIEMCFBTMREQJC-UHFFFAOYSA-N 0.000 claims 1
- HPLVGEMALJKBGT-UHFFFAOYSA-N (7-chloro-1-methyl-3,4-dihydro-1h-isoquinolin-2-yl)-(6-chloropyrazolo[1,5-a]pyrimidin-2-yl)methanone Chemical compound C1=C2N=CC(Cl)=CN2N=C1C(=O)N1C(C)C2=CC(Cl)=CC=C2CC1 HPLVGEMALJKBGT-UHFFFAOYSA-N 0.000 claims 1
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 claims 1
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 claims 1
- ICLMDDKGPWHPFC-UHFFFAOYSA-N 2-(6-bromopyrazolo[1,5-a]pyrimidine-2-carbonyl)-3,4-dihydro-1h-isoquinoline-5-carbonitrile Chemical compound C1CC(C(=CC=C2)C#N)=C2CN1C(=O)C1=NN(C=C(Br)C=N2)C2=C1 ICLMDDKGPWHPFC-UHFFFAOYSA-N 0.000 claims 1
- BBUXWRRZSFDYFI-UHFFFAOYSA-N 7-(6-bromopyrazolo[1,5-a]pyrimidine-2-carbonyl)-2,6-dimethyl-1,6,8,9-tetrahydropyrrolo[3,4-f]isoquinolin-3-one Chemical compound C1=C2N=CC(Br)=CN2N=C1C(=O)N1C(C)C2=CC=C3C(=O)N(C)CC3=C2CC1 BBUXWRRZSFDYFI-UHFFFAOYSA-N 0.000 claims 1
- FDXWCRUHPKYFHS-UHFFFAOYSA-N 7-(6-bromopyrazolo[1,5-a]pyrimidine-2-carbonyl)-2,6-dimethyl-3,6,8,9-tetrahydropyrrolo[3,4-f]isoquinolin-1-one Chemical compound C1=C2N=CC(Br)=CN2N=C1C(=O)N1C(C)C2=CC=C3CN(C)C(=O)C3=C2CC1 FDXWCRUHPKYFHS-UHFFFAOYSA-N 0.000 claims 1
- 208000030507 AIDS Diseases 0.000 claims 1
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 claims 1
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 claims 1
- 208000008811 Agoraphobia Diseases 0.000 claims 1
- 206010003571 Astrocytoma Diseases 0.000 claims 1
- 208000009017 Athetosis Diseases 0.000 claims 1
- 206010003805 Autism Diseases 0.000 claims 1
- 208000020706 Autistic disease Diseases 0.000 claims 1
- 208000020925 Bipolar disease Diseases 0.000 claims 1
- JJDTYNWNAJIZQT-UHFFFAOYSA-N BrC1=C2CCN(CC2=CC=C1)C(=O)C1=NN2C(N=CC(=C2)Cl)=C1.BrC1=C2CCN(CC2=CC=C1)C(=O)C1=NN2C(N=CC(=C2)Br)=C1 Chemical compound BrC1=C2CCN(CC2=CC=C1)C(=O)C1=NN2C(N=CC(=C2)Cl)=C1.BrC1=C2CCN(CC2=CC=C1)C(=O)C1=NN2C(N=CC(=C2)Br)=C1 JJDTYNWNAJIZQT-UHFFFAOYSA-N 0.000 claims 1
- WJACEBXNPDTFNH-UHFFFAOYSA-N BrC=1C=NC=2N(C1)N=C(C2)C(=O)N2C(C1=CC=CC=C1CC2)CCC.ClC=2C=NC=1N(C2)N=C(C1)C(=O)N1C(C2=CC=CC=C2CC1)C1CCCCC1 Chemical compound BrC=1C=NC=2N(C1)N=C(C2)C(=O)N2C(C1=CC=CC=C1CC2)CCC.ClC=2C=NC=1N(C2)N=C(C1)C(=O)N1C(C2=CC=CC=C2CC1)C1CCCCC1 WJACEBXNPDTFNH-UHFFFAOYSA-N 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010006550 Bulimia nervosa Diseases 0.000 claims 1
- 208000011691 Burkitt lymphomas Diseases 0.000 claims 1
- 206010058019 Cancer Pain Diseases 0.000 claims 1
- 201000009030 Carcinoma Diseases 0.000 claims 1
- 206010008748 Chorea Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 208000011990 Corticobasal Degeneration Diseases 0.000 claims 1
- 206010012218 Delirium Diseases 0.000 claims 1
- 208000024254 Delusional disease Diseases 0.000 claims 1
- 206010012335 Dependence Diseases 0.000 claims 1
- 201000010374 Down Syndrome Diseases 0.000 claims 1
- 206010058314 Dysplasia Diseases 0.000 claims 1
- 208000020564 Eye injury Diseases 0.000 claims 1
- 208000010235 Food Addiction Diseases 0.000 claims 1
- 208000001914 Fragile X syndrome Diseases 0.000 claims 1
- 208000018522 Gastrointestinal disease Diseases 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 208000032612 Glial tumor Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 208000031886 HIV Infections Diseases 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 claims 1
- 208000035154 Hyperesthesia Diseases 0.000 claims 1
- 208000013016 Hypoglycemia Diseases 0.000 claims 1
- 206010021143 Hypoxia Diseases 0.000 claims 1
- 201000008197 Laryngitis Diseases 0.000 claims 1
- 208000019693 Lung disease Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 208000000172 Medulloblastoma Diseases 0.000 claims 1
- 208000026072 Motor neurone disease Diseases 0.000 claims 1
- 208000016285 Movement disease Diseases 0.000 claims 1
- 208000001089 Multiple system atrophy Diseases 0.000 claims 1
- 208000007101 Muscle Cramp Diseases 0.000 claims 1
- 208000008238 Muscle Spasticity Diseases 0.000 claims 1
- 208000036572 Myoclonic epilepsy Diseases 0.000 claims 1
- 208000037212 Neonatal hypoxic and ischemic brain injury Diseases 0.000 claims 1
- 208000034179 Neoplasms, Glandular and Epithelial Diseases 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 208000002537 Neuronal Ceroid-Lipofuscinoses Diseases 0.000 claims 1
- 206010057852 Nicotine dependence Diseases 0.000 claims 1
- 208000001294 Nociceptive Pain Diseases 0.000 claims 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 claims 1
- 208000009565 Pharyngeal Neoplasms Diseases 0.000 claims 1
- 206010034811 Pharyngeal cancer Diseases 0.000 claims 1
- 206010034912 Phobia Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 102000029797 Prion Human genes 0.000 claims 1
- 108091000054 Prion Proteins 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 claims 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims 1
- 206010067171 Regurgitation Diseases 0.000 claims 1
- 206010057190 Respiratory tract infections Diseases 0.000 claims 1
- 208000017442 Retinal disease Diseases 0.000 claims 1
- 206010038923 Retinopathy Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 208000020186 Schizophreniform disease Diseases 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 208000005392 Spasm Diseases 0.000 claims 1
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000011963 Substance-induced psychotic disease Diseases 0.000 claims 1
- 231100000393 Substance-induced psychotic disorder Toxicity 0.000 claims 1
- 201000009594 Systemic Scleroderma Diseases 0.000 claims 1
- 206010042953 Systemic sclerosis Diseases 0.000 claims 1
- 206010043118 Tardive Dyskinesia Diseases 0.000 claims 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 claims 1
- 208000025569 Tobacco Use disease Diseases 0.000 claims 1
- 206010043903 Tobacco abuse Diseases 0.000 claims 1
- 206010044074 Torticollis Diseases 0.000 claims 1
- 208000000323 Tourette Syndrome Diseases 0.000 claims 1
- 208000016620 Tourette disease Diseases 0.000 claims 1
- 206010044565 Tremor Diseases 0.000 claims 1
- 206010044688 Trisomy 21 Diseases 0.000 claims 1
- 206010046543 Urinary incontinence Diseases 0.000 claims 1
- 208000028938 Urination disease Diseases 0.000 claims 1
- 206010047700 Vomiting Diseases 0.000 claims 1
- 230000002378 acidificating effect Effects 0.000 claims 1
- 208000005298 acute pain Diseases 0.000 claims 1
- 206010001584 alcohol abuse Diseases 0.000 claims 1
- 208000025746 alcohol use disease Diseases 0.000 claims 1
- 206010053552 allodynia Diseases 0.000 claims 1
- 150000001412 amines Chemical class 0.000 claims 1
- 201000002472 amphetamine abuse Diseases 0.000 claims 1
- 125000001769 aryl amino group Chemical group 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 206010005159 blepharospasm Diseases 0.000 claims 1
- 230000000744 blepharospasm Effects 0.000 claims 1
- 208000029028 brain injury Diseases 0.000 claims 1
- 230000021164 cell adhesion Effects 0.000 claims 1
- 230000004709 cell invasion Effects 0.000 claims 1
- 230000012292 cell migration Effects 0.000 claims 1
- 230000007541 cellular toxicity Effects 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 claims 1
- 208000012601 choreatic disease Diseases 0.000 claims 1
- 201000009243 chronic laryngitis Diseases 0.000 claims 1
- 201000001272 ***e abuse Diseases 0.000 claims 1
- 201000006145 ***e dependence Diseases 0.000 claims 1
- 230000001149 cognitive effect Effects 0.000 claims 1
- 230000037410 cognitive enhancement Effects 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 claims 1
- 125000004122 cyclic group Chemical group 0.000 claims 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 206010013663 drug dependence Diseases 0.000 claims 1
- 208000009985 drug-induced dyskinesia Diseases 0.000 claims 1
- 201000006549 dyspepsia Diseases 0.000 claims 1
- 208000010118 dystonia Diseases 0.000 claims 1
- 201000009028 early myoclonic encephalopathy Diseases 0.000 claims 1
- 230000001037 epileptic effect Effects 0.000 claims 1
- 208000010932 epithelial neoplasm Diseases 0.000 claims 1
- 201000006517 essential tremor Diseases 0.000 claims 1
- 201000002904 focal dystonia Diseases 0.000 claims 1
- 210000001652 frontal lobe Anatomy 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 230000007160 gastrointestinal dysfunction Effects 0.000 claims 1
- 201000002886 generalized dystonia Diseases 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 229960003878 haloperidol Drugs 0.000 claims 1
- 208000007386 hepatic encephalopathy Diseases 0.000 claims 1
- 208000029824 high grade glioma Diseases 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 208000013403 hyperactivity Diseases 0.000 claims 1
- 206010020718 hyperplasia Diseases 0.000 claims 1
- 230000002218 hypoglycaemic effect Effects 0.000 claims 1
- 230000007954 hypoxia Effects 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 208000018197 inherited torticollis Diseases 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 claims 1
- 201000003723 learning disability Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005249 lung adenocarcinoma Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000002780 macular degeneration Diseases 0.000 claims 1
- 208000030883 malignant astrocytoma Diseases 0.000 claims 1
- WSFSSNUMVMOOMR-BJUDXGSMSA-N methanone Chemical compound O=[11CH2] WSFSSNUMVMOOMR-BJUDXGSMSA-N 0.000 claims 1
- 150000004702 methyl esters Chemical class 0.000 claims 1
- 238000013508 migration Methods 0.000 claims 1
- 230000004065 mitochondrial dysfunction Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 208000005264 motor neuron disease Diseases 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 239000003703 n methyl dextro aspartic acid receptor blocking agent Substances 0.000 claims 1
- UCSVNXCGFUCALL-UHFFFAOYSA-N n-[2-(6-bromopyrazolo[1,5-a]pyrimidine-2-carbonyl)-1-methyl-3,4-dihydro-1h-isoquinolin-5-yl]acetamide Chemical compound C1=C2N=CC(Br)=CN2N=C1C(=O)N1C(C)C2=CC=CC(NC(C)=O)=C2CC1 UCSVNXCGFUCALL-UHFFFAOYSA-N 0.000 claims 1
- YPAZKDWFHAURKN-UHFFFAOYSA-N n-[2-(6-chloropyrazolo[1,5-a]pyrimidine-2-carbonyl)-1-methyl-3,4-dihydro-1h-isoquinolin-5-yl]acetamide Chemical compound C1=C2N=CC(Cl)=CN2N=C1C(=O)N1C(C)C2=CC=CC(NC(C)=O)=C2CC1 YPAZKDWFHAURKN-UHFFFAOYSA-N 0.000 claims 1
- 230000009826 neoplastic cell growth Effects 0.000 claims 1
- 210000000944 nerve tissue Anatomy 0.000 claims 1
- 230000000626 neurodegenerative effect Effects 0.000 claims 1
- 208000018360 neuromuscular disease Diseases 0.000 claims 1
- 201000008051 neuronal ceroid lipofuscinosis Diseases 0.000 claims 1
- 230000004112 neuroprotection Effects 0.000 claims 1
- 206010029864 nystagmus Diseases 0.000 claims 1
- 208000031237 olivopontocerebellar atrophy Diseases 0.000 claims 1
- 201000005040 opiate dependence Diseases 0.000 claims 1
- 229940124636 opioid drug Drugs 0.000 claims 1
- 201000002740 oral squamous cell carcinoma Diseases 0.000 claims 1
- 208000002851 paranoid schizophrenia Diseases 0.000 claims 1
- 208000033300 perinatal asphyxia Diseases 0.000 claims 1
- 230000002093 peripheral effect Effects 0.000 claims 1
- 210000001428 peripheral nervous system Anatomy 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 208000019899 phobic disease Diseases 0.000 claims 1
- 230000002980 postoperative effect Effects 0.000 claims 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims 1
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 claims 1
- 208000020029 respiratory tract infectious disease Diseases 0.000 claims 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims 1
- 201000003068 rheumatic fever Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 208000022610 schizoaffective disease Diseases 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 208000019116 sleep disease Diseases 0.000 claims 1
- 208000018198 spasticity Diseases 0.000 claims 1
- 210000000278 spinal cord Anatomy 0.000 claims 1
- 208000020431 spinal cord injury Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 238000003786 synthesis reaction Methods 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 201000008914 temporal lobe epilepsy Diseases 0.000 claims 1
- 150000003536 tetrazoles Chemical class 0.000 claims 1
- 239000002562 thickening agent Substances 0.000 claims 1
- DLFVBJFMPXGRIB-UHFFFAOYSA-N thioacetamide Natural products CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims 1
- 229930192474 thiophene Natural products 0.000 claims 1
- 208000008732 thymoma Diseases 0.000 claims 1
- 208000016686 tic disease Diseases 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- 231100000419 toxicity Toxicity 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
- 230000004565 tumor cell growth Effects 0.000 claims 1
- 210000001635 urinary tract Anatomy 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
- 230000008673 vomiting Effects 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
- 125000005167 cycloalkylaminocarbonyl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Abstract
Spoj pirazolopirimidina formule (I) pri čemu Y1 predstavlja N ili C-,Y2 predstavlja N ili C-,Y3 predstavlja N ili C-,Y4 predstavlja N ili C-,pri čemu barem dvije od skupina Y1 do Y4 označavaju atom ugljika, R1 predstavlja kloro ili bromo; R2 i R3 svaki zasebno predstavljaju vodik, C1-6alkil, C3-7cikloalkil ili trifluorometil; iliR2 i R3 oba zajedno sa atomom ugljika iz prstena predstavljaju karbonilnu skupinu; R4 i R5 svaki zasebno predstavljaju vodik, C1-6alkil, C3-7cikloalkil ili trifluorometil; iliR4 i R5 oba zajedno sa atomom ugljika iz prstena predstavljaju karbonilnu skupinu; R6 i R7 zasebno predstavljaju vodik, C1-6alkil, C3-7cikloalkil ili trifluorometil; iliR6 i R7 oba zajedno sa atomom ugljika iz prstena predstavljaju karbonilnu skupinu;R2 i R3 zajedno sa R6 R7 mogu također tvoriti bivalentni radikal iz skupine CH2-CH2 ili CH2-O; R10 i R11 neovisno predstavljaju vodik, halogen, amino, hidroksi, nitro, cijano, trifluorometil, trifluorometoksi, aril, C1-6alkil, C3-7cikloalkil, C2-6alkenil, C2-6alkinil, C1-6alkoksi, C3-7-cilkoalkiloksi, C2-6alkeniloksi, C2-6alkiniloksi, heteroaril, heterociklil, ariloksi, heteroariloksi, heterocikliloksi, C1-6alkilamino, di-C16alkilamino, C3-7-cikloalkilamino, di-C3-7-cikloalkilamino, C1-6alkil-C3-7-cikloalkilamino, C2-6alenilamino, C2-6alkinilamino, di-C2-6alkenilamino, di-C2-6alkinilamino, C1-6alkil-C2-6alkenilamino, C1-6alkil-C2-6alkinilamino, C2-6alkenil-C3-7-cikloalkilamino, C2-6alkinil-C3-7-cikloalkilamino, C2-6alkenil-C2-6-alkinilamino arilamino, diarilamino, aril-C1-6alkilamino, aril-C2-6alkenilamino, aril-C2-6alkinilamino, aril-C3-7-cikloalkilamino, heteroarilamino, diheteroarilamino, heteroaril-C1-6alkilamino, heteroaril-C2-6alkenilamino, heteroaril-C2-6alkinilamino, heteroaril-C3-7-cikloalkilamino, heteroarilarilamino, heterociklilamino, diheterociklilamino, heterociklil-C1-6alkilamino, heterociklil-C2-6alkenilamino, heterociklil-C2-6alkinilamino, heterociklil-C3-7-cikloalkilamino, heterociklilarilamino, heterociklilhetero-arilamino, acil, aciloksi, acilamino, C16alkoksikarbonil, C3-7-cikloalkoksi-karbonil, C2-6alkeniloksikarbonil, C26alkiniloksikarbonil, ariloksikarbonil, heteroariloksikarbonil, heterocikliloksikarbonil, aminokarbonil, C1-6alkilamino-karbonil, di-C1-6alkilaminokarbonil, C3-7-cikloalkilaminokarbonil, di-C3-7-cikloalkilaminokarbonil, C1-6alkil-C3-7-cikloalkilaminokarbonil, C2-6alkenil-aminokarbonil, C2-6alkinilaminokarbonil, di-C2-6alkenilaminokarbonil, di-C2-6alkinilaminokarbonil, C1-6alkil-C2-6-alkenilaminokarbonil, C1-6alkil-C2-6-alkinil-aminokarbonil, C2-6alkenil-C3-7-cikloalkilaminokarbonil, C2-6alkinil-C3-7-cikloalkilaminokarbonil, C2-6alkenil-C2-6-alkinilaminokarbonil, arilaminokarbonil, diarilaminokarbonil, aril-C1-6alkilaminokarbonil, aril-C2-6alkenilaminokarbonil, aril-C2-6alkinilaminokarbonil, aril-C3-7-cikloalkilaminokarbonil, heteroarilaminokarbonil, diheteroarilaminokarbonil, heteroaril-C1-6alkilaminokarbonil, heteroaril-C2-6alkenilaminokarbonil, heteroaril-C2-6alki
Claims (17)
1. Spoj pirazolopirimidina formule (I)
[image]
pri čemu
Y1 predstavlja N ili C-,
Y2 predstavlja N ili C-,
Y3 predstavlja N ili C-,
Y4 predstavlja N ili C-,
pri čemu barem dvije od skupina Y1 do Y4 označavaju atom ugljika,
R1 predstavlja kloro ili bromo;
R2 i R3 svaki zasebno predstavljaju vodik, C1-6alkil, C3-7cikloalkil ili trifluorometil; ili
R2 i R3 oba zajednosa atomom ugljika iz prstena predstavljaju karbonilnu skupinu; R4 i R5 svaki zasebno predstavljaju vodik, C1-6alkil, C3-7cikloalkil ili trifluorometil; ili
R4 i R5 oba zajednosa atomom ugljika iz prstena predstavljaju karbonilnu skupinu; R6 i R7 zasebno predstavljaju vodik, C1-6alkil, C3-7cikloalkil ili trifluorometil; ili
R6 i R7 oba zajednosa atomom ugljika iz prstena predstavljaju karbonilnu skupinu;R2 i R3 zajedno sa R6 R7 mogu također tvoriti bivalentni radikal iz skupine CH2-CH2 ili CH2-O;
R10 i R11 neovisno predstavljaju vodik, halogen, amino, hidroksi, nitro, cijano, trifluorometil, trifluorometoksi, aril, C1-6alkil, C3-7cikloalkil, C2-6alkenil, C2-6alkinil, C1-6alkoksi, C3-7-cilkoalkiloksi, C2-6alkeniloksi, C2-6alkiniloksi, heteroaril, heterociklil, ariloksi, heteroariloksi, heterocikliloksi, C1-6alkilamino, di-C16alkilamino, C3-7-cikloalkilamino, di-C3-7-cikloalkilamino, C1-6alkil-C3-7-cikloalkilamino, C2-6alenilamino, C2-6alkinilamino, di-C2-6alkenilamino, di-C2-6alkinilamino, C1-6alkil-C2-6alkenilamino, C1-6alkil-C2-6alkinilamino, C2-6alkenil-C3-7-cikloalkilamino, C2-6alkinil-C3-7-cikloalkilamino, C2-6alkenil-C2-6-alkinilamino arilamino, diarilamino, aril-C1-6alkilamino, aril-C2-6alkenilamino, aril-C2-6alkinilamino, aril-C3-7-cikloalkilamino, heteroarilamino, diheteroarilamino, heteroaril-C1-6alkilamino, heteroaril-C2-6alkenilamino, heteroaril-C2-6alkinilamino, heteroaril-C3-7-cikloalkilamino, heteroarilarilamino, heterociklilamino, diheterociklilamino, heterociklil-C1-6alkilamino, heterociklil-C2-6alkenilamino, heterociklil-C2-6alkinilamino, heterociklil-C3-7-cikloalkilamino, heterociklilarilamino, heterociklilhetero-arilamino, acil, aciloksi, acilamino, C16alkoksikarbonil, C3-7-cikloalkoksi-karbonil, C2-6alkeniloksikarbonil, C26alkiniloksikarbonil, ariloksikarbonil, heteroariloksikarbonil, heterocikliloksikarbonil, aminokarbonil, C1-6alkilamino-karbonil, di-C1-6alkilaminokarbonil, C3-7-cikloalkilaminokarbonil, di-C3-7-cikloalkilaminokarbonil, C1-6alkil-C3-7-cikloalkilaminokarbonil, C2-6alkenil-aminokarbonil, C2-6alkinilaminokarbonil, di-C2-6alkenilaminokarbonil, di-C2-6alkinilaminokarbonil, C1-6alkil-C2-6-alkenilaminokarbonil, C1-6alkil-C2-6-alkinil-aminokarbonil, C2-6alkenil-C3-7-cikloalkilaminokarbonil, C2-6alkinil-C3-7-cikloalkilaminokarbonil, C2-6alkenil-C2-6-alkinilaminokarbonil, arilaminokarbonil, diarilaminokarbonil, aril-C1-6alkilaminokarbonil, aril-C2-6alkenilaminokarbonil, aril-C2-6alkinilaminokarbonil, aril-C3-7-cikloalkilaminokarbonil, heteroarilaminokarbonil, diheteroarilaminokarbonil, heteroaril-C1-6alkilaminokarbonil, heteroaril-C2-6alkenilaminokarbonil, heteroaril-C2-6alkinilaminokarbonil, heteroaril-C3-7-cikloalkilaminokarbonil, heteroarilarilaminokarbonil, heterociklilaminokarbonil, diheterociklilaminokarbonil, heterociklil-C1-6alkilaminokarbonil, heterociklil-C2-6alkenilaminokarbonil, heterociklil-C2-6alkinilaminokarbonil, heterociklil-C3-7-cikloalkilaminokarbonil, heterociklilarilaminokarbonil, heterociklilheteroarilaminokarbonil, C1-6alkilsulfinil, C3-7-cikloalkilsulfinil, C2-6alkenilsulfinil, C2-6alkinilsulfinil, arilsulfinil, heteroarilsulfinil, heterociklilsulfinil, C1-6alkilsulfonil, C3-7-cikloalkilsulfonil, C2-6alkenilsulfonil, C2-6alkinilsulfonil, arilsulfonil, heteroarilsulfonil, heterociklilsulfonil, C1-6alkilsulfonilamino, ili arilsulfonilamino;
ili R10 i R11 zajedno sa dva atoma ugljika koji ih nose predstavljaju heteroaril koji ima 5 ili 6 članova prstena ili heterociklilna skupina koja ima 5 ili 6 članova prstena, koji se mogu zamijeniti sa jednom od slijedećih skupina: halogen, hidroksi, nitro, cijano, trifluorometil, trifluorometoksi, C1-6alkil i C1-6alkoksi;
i njihovim optičkim izomerima, farmaceutski prihvatljivim solima, hidratima, otopinama, polimorfima, pod uvjetom da spoj iz formule (I) ne predstavlja spoj (6- bromo- pirazolo [1,5- a] pirimidin- 2- il)- (3,4- dihidro- 1H- izokvinolin- 2- il)- metanona.
2. Spoj iz formule (I) temeljem zahtjeva 1, pri čemu R10 i R11 nezavisno predstavljaju vodik, halogen, amino, hidroksil, nitro, cijano, trifluorometil, trifluorometoksi, C1-C6alkil, C1-C6alkiloksi, cikloheksil, fenil, ili prstenasi sustav iz skupine: tiofena, pirola, furana, pirazola, tetrazola, oksazola, izoksazola, tiazola, piridina, pirimidina i morfolina.
3. Spoj iz formule (I) temeljem bilo kojeg od zahtjeva 1 do 2, pri čemu jedan od R2 i R3 predstavlja metil, etil ili trifluorometil, a preostali R2 i R3 predstavlja vodik.
4. Spoj iz formule (I) temeljem jednog od zahtjeva 1 do 3, pri čemu R2, R3, R4, R5, R6 i R7 samostalno predstavljaju vodik, metil ili etil.
5. Spoj iz formule (I) temeljem bilo kojeg od zahtjeva 1 do 4, pri čemu R2 predstavlja metil ili etil, a R3, R4, R5, R6, R7 predstavljaju vodik i koji ima barem jedan kiralni atom ugljika u R-konfiguraciji.
6. Spoj iz formule (I) temeljem bilo kojeg od zahtjeva 1 do 4, pri čemu R2 predstavlja metil ili etil, a R3, R4, R5, R6, R7 predstavljaju vodik i koji ima barem jedan kiralni atom ugljika u S-konfiguraciji.
7. Spoj iz formule (I) temeljem bilo kojeg od zahtjeva 1 do 6, pri čemu Y’, Y2, Y3 i Y4 svi predstavljaju atom ugljika.
8. Spoj iz formule (I) temeljem bilo kojeg od zahtjeva 1 do 7, pri čemu R1 označava kloro.
9. Spoj iz formule (I) temeljem bilo kojeg od zahtjeva 1 do 7, pri čemu R1 označava bromo.
10. Spoj iz formule (I) temeljem zahtjeva 1 i koji ima jedan od slijedećih kemijskih naziva:
(6- bromo- pirazolo [1,5- a] pirimidin- 2- il) – (6- hidroksi- 7- metoksi- 1- metil- 3,4- dihidro- 1H- izokvinolin- 2- il)- metanon
(6- kloro- pirazolo [1,5- a] pirimidin- 2- il) – (1- metil- 3,4- dihidro- 1H- izokvinolin- 2- il)- metanon
(6- kloro- pirazolo [1,5- a] pirimidin- 2- il) – (3- metil- 3,4- dihidro- 1H- izokvinolin- 2- il)- metanon
(6- bromo- pirazolo [1,5- a] pirimidin- 2- il) – (3- metil- 3,4- dihidro- 1H- izokvinolin- 2- il)- metanon
(6- bromo- pirazolo [1,5- a] pirinfidin- 2- il) – (3,3- dimetil- 3,4- dihidro- 1H- izokvinolin- 2- il)- metanon
(6- kloro- pirazolo [1,5- a] pirimidin- 2- il) – (3,3- dimetil- 3,4- dihidro- 1H- izokvinolin- 2- il)- metanon
(6- kloro- pirazolo [1,5- a] pirimidin- 2- il) – (3,4- dihidro- 1H- izokvinolin- 2- il)- metanon
(6- kloro- pirazolo [1,5- a] pirimidin- 2- il) – (6,7- dimetoksi- 1- metil- 3,4- dihidro- 1H- izokvinolin- 2- il)- metanon
(6- kloro- pirazolo [1,5- a] pirimidin- 2- il) – (6,7- dimetoksi- 3,4- dihidro- 1H- izokvinolin- 2- il)- metanon
(6- bromo- pirazolo [1,5- a] pirimidin- 2- il) – (6,7- dimetoksi- 3,4- dihidro- 1H- izokvinolin- 2- il)- metanon
(6- bromo- pirazolo [1,5- a] pirimidin- 2- il) – (6,7- dimetoksi- 1- metil- 3,4- dihidro- 1H- izokvinolin- 2- il)- metanon
(6- kloro- pirazolo [1,5- a] pirimidin- 2- il) – (6- hidroksi- 7- metoksi- 3,4- dihidro- 1H- izokvinolin- 2- il)- metanon
(6- kloro- pirazolo [1,5- a] pirimidin- 2- il) – (6- hidroksi- 7- metoksi- 1- metil- 3,4- dihidro- 1H- izokvinolin- 2- il)- metanon
(6- bromo- pirazolo [1,5- a] pirimidin- 2- il) – (6,7- dimetoksi- 3- metil- 3,4- dihidro- 1H- izokvinolin- 2- il)- metanon
(6- kloro- pirazolo [1,5- a] pirimidin- 2- il) – (6,7- dimetoksi- 3- metil- 3,4- dihidro- 1H- izokvinolin- 2- il)- metanon
(6- bromo- pirazolo [1,5- a] pirimidin- 2- il) – (6,7- dimetoksi- 3,3- dimetil- 3,4- dihidro- 1H- izokvinolin- 2- il)- metanon
(6- kloro- pirazolo [1,5- a] pirimidin- 2- il) – (6,7- dimetoksi- 3,3- dimetil- 3,4- dihidro- 1H- izokvinolin- 2- il)- metanon
(6- bromo- pirazolo [1,5- a] pirimidin- 2- il) – (8- metil- 5,8- dihidro- 6H- [1,7] nafthidrin- 7- il)- metanon
(6- kloro- pirazolo [1,5- a] pirimidin- 2- il) – (8- metil- 5,8- dihidro- 6H- [1,7] nafthidrin- 7- il)- metanon
(6- bromo- pirazolo [1,5- a] pirimidin- 2- il) – (1- metil- 3,4- dihidro- 1H- [2,7] nafthidrin- 2- il)- metanon
(6- kloro- pirazolo [1,5- a] pirimidin- 2- il) – (1- metil- 3,4- dihidro- 1H- [2,7] nafthidrin- 2- il)- metanon
(6- bromo- pirazolo [1,5- a] pirimidin- 2- il) – (1- metil- 3,4- dihidro- 1H- [2,6] nafthidrin- 2- il)- metanon
(6- kloro- pirazolo [1,5- a] pirimidin- 2- il) – (1- metil- 3,4- dihidro- 1H- [2,6] nafthidrin- 2- il)- metanon
(6- bromo- pirazolo [1,5- a] pirimidin- 2- il) – (5- metil- 7,8- dihidro- 5H- [1,6] nafthidrin- 6- il)- metanon
(6- kloro- pirazolo [1,5- a] pirimidin- 2- il) – (5- metil- 7,8- dihidro- 5H- [1,6] nafthidrin- 6- il)- metanon
(6- bromo- pirazolo [1,5- a] pirimidin- 2- il) – (1- metil- 3,4- dihidro- 1H- izokvinolin- 2- il)- metanon
(6- bromo- pirazolo [1,5- a] pirimidin- 2- il) – (3,4- dihidro- 1H- izokvinolin- 2- il)- metanon
(6- bromo- pirazolo [1,5- a] pirimidin- 2- il) – (7- fluoro- 1- metil- 3,4- dihidro- 1H- izokvinolin- 2- il)- metanon
(6- bromo- pirazolo [1,5- a] pirimidin- 2- il) – (7- fluoro- 1- metil- 3,4- dihidro- 1H- izokvinolin- 2- il)- metanon
(6- bromo- pirazolo [1,5- a] pirimidin- 2- il) – (7- fluoro- 1- metil- 3,4- dihidro- 1H- izokvinolin- 2- il)- metanon
(6- bromo- pirazolo [1,5- a] pirimidin- 2- il) – (8- fluoro- 1- metil- 3,4- dihidro- 1H- izokvinolin- 2- il)- metanon
(6- bromo- pirazolo [1,5- a] pirimidin- 2- il) – (6- fluoro- 1- metil- 3,4- dihidro- 1H- izokvinolin- 2- il)- metanon
(6- bromo- pirazolo [1,5- a] pirimidin- 2- il) – (5- fluoro- 1- metil- 3,4- dihidro- 1H- izokvinolin- 2- il)- metanon
(6- kloro- pirazolo [1,5- a] pirimidin- 2- il) – (7- fluoro- 1- metil- 3,4- dihidro- 1H- izokvinolin- 2- il)- metanon
(6- kloro- pirazolo [1,5- a] pirimidin- 2- il) – (8- fluoro- 1- metil- 3,4- dihidro- 1H- izokvinolin- 2- il)- metanon
(6- kloro- pirazolo [1,5- a] pirimidin- 2- il) – (6- fluoro- 1- metil- 3,4- dihidro- 1H- izokvinolin- 2- il)- metanon
(6- kloro- pirazolo [1,5- a] pirimidin- 2- il) – (5- fluoro- 1- metil- 3,4- dihidro- 1H- izokvinolin- 2- il)- metanon
(6- bromo- pirazolo [1,5- a] pirimidin- 2- il) – (8- fluoro- 1- etil- 3,4- dihidro- 1H- izokvinolin- 2- il)- metanon
(6- bromo- pirazolo [1,5- a] pirimidin- 2- il) – (7- fluoro- 1- etil- 3,4- dihidro- 1H- izokvinolin- 2- il)- metanon
(6- bromo- pirazolo [1,5- a] pirimidin- 2- il) – (6- fluoro- 1- etil- 3,4- dihidro- 1H- izokvinolin- 2- il)- metanon
(6- bromo- pirazolo [1,5- a] pirimidin- 2- il) – (5- fluoro- 1- etil- 3,4- dihidro- 1H- izokvinolin- 2- il)- metanon
(6- kloro- pirazolo [1,5- a] pirimidin- 2- il) – (8- fluoro- 1- etil- 3,4- dihidro- 1H- izokvinolin- 2- il)- metanon
(6- kloro- pirazolo [1,5- a] pirimidin- 2- il) – (7- fluoro- 1- etil- 3,4- dihidro- 1H- izokvinolin- 2- il)- metanon
(6- kloro- pirazolo [1,5- a] pirimidin- 2- il) – (6- fluoro- 1- etil- 3,4- dihidro- 1H- izokvinolin- 2- il)- metanon
(6- kloro- pirazolo [1,5- a] pirimidin- 2- il) – (5- fluoro- 1- etil- 3,4- dihidro- 1H- izokvinolin- 2- il)- metanon
(6- bromo- pirazolo [1,5- a] pirimidin- 2- il) – (8- fluoro- 1- trifluorometil- 3,4- dihidro- 1H- izokvinolin- 2- il)- metanon
(6- bromo- pirazolo [1,5- a] pirimidin- 2- il) – (7- fluoro- 1- trifluorometil- 3,4- dihidro- 1H- izokvinolin- 2- il)- metanon
(6- bromo- pirazolo [1,5- a] pirimidin- 2- il) – (6- fluoro- 1- trifluorometil- 3,4- dihidro- 1H- izokvinolin- 2- il)- metanon
(6- bromo- pirazolo [1,5- a] pirimidin- 2- il) – (5- fluoro- 1- trifluorometil- 3,4- dihidro- 1H- izokvinolin- 2- il)- metanon
(6- kloro- pirazolo [1,5- a] pirimidin- 2- il) – (8- fluoro- 1- trifluorometil- 3,4- dihidro- 1H- izokvinolin- 2- il)- metanon
(6- kloro- pirazolo [1,5- a] pirimidin- 2- il) – (7- fluoro- 1- trifluorometil- 3,4- dihidro- 1H- izokvinolin- 2- il)- metanon
(6- kloro- pirazolo [1,5- a] pirimidin- 2- il) – (6- fluoro- 1- trifluorometil- 3,4- dihidro- 1H- izokvinolin- 2- il)- metanon
(6- kloro- pirazolo [1,5- a] pirimidin- 2- il) – (5- fluoro- 1- trifluorometil- 3,4- dihidro- 1H- izokvinolin- 2- il)- metanon
(6- bromo- pirazolo [1,5- a] pirimidin- 2- il) – (3- etil- 1- metil- 3,4- dihidro- 1H- izokvinolin- 2- il)- metanon
(6- bromo- pirazolo [1,5- a] pirimidin- 2- il) – ((R)- 3- metil- 3,4- dihidro- 1H- izokvinolin- 2- il)- metanon
(6- bromo- pirazolo [1,5- a] pirimidin- 2- il) – ((S)- 3- metil- 3,4- dihidro- 1H- izokvinolin- 2- il)- metanon
(6- kloro- pirazolo [1,5- a] pirimidin- 2- il) – (1- metil- 3,4- dihidro- 1H- izokvinolin- 2- il)- metanon
(7- bromo- 3,4- dihidro- 1H- izokvinolin- 2- il)- (6- kloro- pirazolo [1,5- a] pirimidin- 2- il)- metanon
(7- bromo- 3,4- dihidro- 1H- izokvinolin- 2- il)- (6- bromo- pirazolo [1,5- a] pirimidin- 2- il)- metanon
(6- kloro- pirazolo [1,5- a] pirimidin- 2- il) – (7- fluoro- 1- metil- 3,4- dihidro- 1H- izokvinolin- 2- il)- metanon
(6- kloro- pirazolo [1,5- a] pirimidin- 2- il) – (1,4- dimetil- 3,4- dihidro- 1H- izokvinolin- 2- il)- metanon
(6- bromo- pirazolo [1,5- a] pirimidin- 2- il) – (1,4- dimetil- 3,4- dihidro- 1H- izokvinolin- 2- il)- metanon
(6- bromo- pirazolo [1,5- a] pirimidin- 2- il) – (1,4- dimetil- 3,4- dihidro- 1H- izokvinolin- 2- il)- metanon
(6- bromo- pirazolo [1,5- a] pirimidin- 2- il) – (1,4- dimetil- 3,4- dihidro- 1H- izokvinolin- 2- il)- metanon
(6- bromo- pirazolo [1,5- a] pirimidin- 2- il) – (1,4- dimetil- 3,4- dihidro- 1H- izokvinolin- 2- il)- metanon
(6- bromo- pirazolo [1,5- a] pirimidin- 2- il) – (1,4- dimetil- 3,4- dihidro- 1H- izokvinolin- 2- il)- metanon
(6- bromo- pirazolo [1,5- a] pirimidin- 2- il) – (6- metoksi- 1- metil- 3,4- dihidro- 1H- izokvinolin- 2- il)- metanon
(6- kloro- pirazolo [1,5- a] pirimidin- 2- il) – (6- metoksi- 1- metil- 3,4- dihidro- 1H- izokvinolin- 2- il)- metanon
(6- bromo- pirazolo [1,5- a] pirimidin- 2- il) – (1- etil- 3,4- dihidro- 1H- izokvinolin- 2- il)- metanon
(6- bromo- pirazolo [1,5- a] pirimidin- 2- il) – (1- izopropil- 3,4- dihidro- 1H- izokvinolin- 2- il)- metanon
(6- kloro- pirazolo [1,5- a] pirimidin- 2- il) – (1- izopropil- 3,4- dihidro- 1H- izokvinolin- 2- il)- metanon
(6- kloro- pirazolo [1,5- a] pirimidin- 2- il) – (1- etil- 3,4- dihidro- 1H- izokvinolin- 2- il)- metanon
(6- bromo- pirazolo [1,5- a] pirimidin- 2- il) – (1- trifluorometil- 3,4- dihidro- 1H- izokvinolin- 2- il)- metanon
(6- kloro- pirazolo [1,5- a] pirimidin- 2- il) – (1- trifluorometil- 3,4- dihidro- 1H- izokvinolin- 2- il)- metanon
(7- bromo- 1- metil- 3,4- dihidro- 1H-izokvinolin- 2- il) – (6- bromo- pirazolo [1,5- a] pirimidin- 2- il)- metanon
(7- bromo- 1- metil- 3,4- dihidro- 1H-izokvinolin- 2- il) – (6- kloro- pirazolo [1,5- a] pirimidin- 2- il)- metanon
(6- bromo- pirazolo [1,5- a] pirimidin- 2- il) – (1- cikloheksil- 3,4- dihidro- 1H- izokvinolin- 2- il)- metanon
(6- kloro- pirazolo [1,5- a] pirimidin- 2- il) – (1- cikloheksil- 3,4- dihidro- 1H- izokvinolin- 2- il)- metanon
(6- bromo- pirazolo [1,5- a] pirimidin- 2- il) – (1- propil- 3,4- dihidro- 1H- izokvinolin- 2- il)- metanon
(6- bromo- pirazolo [1,5- a] pirimidin- 2- il) – ((S)1- metil- 3,4- dihidro- 1H- izokvinolin- 2- il)- metanon
(6- bromo- pirazolo [1,5- a] pirimidin- 2- il) – ((R)1- metil- 3,4- dihidro- 1H- izokvinolin- 2- il)- metanon
(5- bromo- 1- metil- 3,4- dihidro- 1H- izokvinolin- 2- il) – (6- kloro- pirazolo [1,5- a] pirimidin- 2- il)- metanon
(6- bromo- pirazolo [1,5- a] pirimidin- 2- il) – (5- metoksi- 1- metil- 3,4- dihidro- 1H- izokvinolin- 2- il)- metanon
(5- bromo- 1- metil- 3,4- dihidro- 1H- izokvinolin- 2- il) – (6- bromo- pirazolo [1,5- a] pirimidin- 2- il)- metanon
(6- bromo- pirazolo [1,5- a] pirimidin- 2- il) – (7- piridin- 4- il- 3,4- dihidro- 1H- izokvinolin- 2- il)- metanon
(6- bromo- pirazolo [1,5- a] pirimidin- 2- il) – (7- metoksi- 1- metil- 3,4- dihidro- 1H- izokvinolin- 2- il)- metanon
(6- kloro- pirazolo [1,5- a] pirimidin- 2- il) – (7- metoksi- 1- metil- 3,4- dihidro- 1H- izokvinolin- 2- il)- metanon
(6- bromo- 1- metil- 3,4- dihidro- 1H- izokvinolin- 2- il) – (6- bromo- pirazolo [1,5- a] pirimidin- 2- il)- metanon
(6- bromo- pirazolo [1,5- a] pirimidin- 2- il) – (5,6- dimetoksi- 1- metil- 3,4- dihidro- 1H- izokvinolin- 2- il)- metanon
(6- bromo- pirazolo [1,5- a] pirimidin- 2- il) – (5,8- difluoro- 1- metil- 3,4- dihidro- 1H- izokvinolin- 2- il)- metanon
(6- kloro- pirazolo [1,5- a] pirimidin- 2- il) – (58- difluoro- 1- metil- 3,4- dihidro- 1H- izokvinolin- 2- il)- metanon
(6- bromo- pirazolo [1,5- a] pirimidin- 2- il) – (1- metil- 5- trifluorometil- 3,4- dihidro- 1H- izokvinolin- 2- il)- metanon
(6- kloro- pirazolo [1,5- a] pirimidin- 2- il) – (1- metil- 5- trifluorometil- 3,4- dihidro- 1H- izokvinolin- 2- il)- metanon
(6- kloro- pirazolo [1,5- a] pirimidin- 2- il) – (5- metil- 7,8- dihidro- 5H- [1,6] nafthidrin- 6- il)- metanon
(3- bromo- 7,8- dihidro- 5H- [1,6] nafthidrin- 6- il) – (6- kloro- pirazolo- [1,5- a] pirimidin- 2- il)- metanon
(6- bromo- pirazolo [1,5- a] pirimidin- 2- il) – (1- metil- 6- piridin- 3- il- 3,4- dihidro- 1H- izokvinolin- 2- il)- metanon
(3- bromo- 7,8- dihidro- 5H- [1,6] nafthidrin- 6- il) – (6- bromo- pirazolo- [1,5- a] pirimidin- 2- il)- metanon
(6- bromo- pirazolo [1,5- a] pirimidin- 2- il) – (1- metil- 7- piridin- 3- il- 3,4- dihidro- 1H- izokvinolin- 2- il)- metanon
2- (6- bromo- pirazolo [1,5- a] pirimidin- 2- karbonil-) 1,2,3,4- tetrahidro- izokvinolin- 7- karbonitril
(6- bromo- pirazolo [1,5- a] pirimidin- 2- il) – (1- metil- 7- piridin- 4- il- 3,4- dihidro- 1H- izokvinolin- 2- il)- metanon
(6- bromo- pirazolo [1,5- a] pirimidin- 2- il) – (5- nitro- 3,4- dihidro- 1H- izokvinolin- 2- il)- metanon
(6- kloro- pirazolo [1,5- a] pirimidin- 2- il) – (5- nitro- 3,4- dihidro- 1H- izokvinolin- 2- il)- metanon
(6- bromo- pirazolo [1,5- a] pirimidin- 2- il) – (1- metil- 7- pirimidin- 5- il- 3,4- dihidro- 1H- izokvinolin- 2- il)- metanon
(6- bromo- pirazolo [1,5- a] pirimidin- 2- il) – (7- morfolin- 4- il- 3,4- dihidro- 1H- izokvinolin- 2- il)- metanon
(6- kloro- pirazolo [1,5- a] pirimidin- 2- il) – (7- morfolin- 4- il- 3,4- dihidro- 1H- izokvinolin- 2- il)- metanon
(6- bromo- pirazolo [1,5- a] pirimidin- 2- il) – (8- morfolin- 4- il- 3,4- dihidro- 1H- izokvinolin- 2- il)- metanon
(6- kloro- pirazolo [1,5- a] pirimidin- 2- il) – (8- morfolin- 4- il- 3,4- dihidro- 1H- izokvinolin- 2- il)- metanon
(6- bromo- pirazolo [1,5- a] pirimidin- 2- il) – (6- morfolin- 4- il- 3,4- dihidro- 1H- izokvinolin- 2- il)- metanon
(6- kloro- pirazolo [1,5- a] pirimidin- 2- il) – (6- morfolin- 4- il- 3,4- dihidro- 1H- izokvinolin- 2- il)- metanon
(6- bromo- pirazolo [1,5- a] pirimidin- 2- il) – (5- morfolin- 4- il- 3,4- dihidro- 1H- izokvinolin- 2- il)- metanon
(6- kloro- pirazolo [1,5- a] pirimidin- 2- il) – (5- morfolin- 4- il- 3,4- dihidro- 1H- izokvinolin- 2- il)- metanon
(6- bromo- pirazolo [1,5- a] pirimidin- 2- il) – (1- metil- 6- pirimidin- 5- il- 3,4- dihidro- 1H- izokvinolin- 2- il)- metanon
(6- bromo- pirazolo [1,5- a] pirimidin- 2- il) – (1- metil- 5- pirimidin- 5- il- 3,4- dihidro- 1H- izokvinolin- 2- il)- metanon
(6- bromo- pirazolo [1,5- a] pirimidin- 2- il) – (1- metil- 5- pirimidin- 3- il- 3,4- dihidro- 1H- izokvinolin- 2- il)- metanon
(3- bromo- 7,8- dihidro- 5H- [1,6] nafthidrin- 6- il) – (6- bromo- pirazolo [1,5- a] pirimidin- 2- il)- metanon
(6- kloro- pirazolo [1,5- a] pirimidin- 2- il) – (1- metil- 7- trifluorometil- 3,4- dihidro- 1H- izokvinolin- 2- il)- metanon
(6- bromo- pirazolo [1,5- a] pirimidin- 2- il) – (1- metil- 7- trifluorometil- 3,4- dihidro- 1H- izokvinolin- 2- il)- metanon
(6- kloro- pirazolo [1,5- a] pirimidin- 2- il) – (1,5- dimetil- 3,4- dihidro- 1H- izokvinolin- 2- il)- metanon
(6- kloro- pirazolo [1,5- a] pirimidin- 2- il) – (1,7- dimetil- 3,4- dihidro- 1H- izokvinolin- 2- il)- metanon
(6- bromo- pirazolo [1,5- a] pirimidin- 2- il) – (1,7- dimetil- 3,4- dihidro- 1H- izokvinolin- 2- il)- metanon
(6- bromo- pirazolo [1,5- a] pirimidin- 2- il) – (1,5- dimetil- 3,4- dihidro- 1H- izokvinolin- 2- il)- metanon
(7- kloro- 1- metil- 3,4- dihidro- 1H- izokvinolin- 2- il) – (6- kloro- pirazolo [1,5- a] pirimidin- 2- il)- metanon
(6- bromo- pirazolo [1,5- a] pirimidin- 2- il) – (7- kloro- 1- metil- 3,4- dihidro- 1H- izokvinolin- 2- il)- metanon
(5- kloro- 1- metil- 3,4- dihidro- 1H- izokvinolin- 2- il) – (6- kloro- pirazolo [1,5- a] pirimidin- 2- il)- metanon
N- [2- kloro- pirazolo [1,5- a] pirimidin- 2- karbonil)- 1,2,3,4- tetrahidro- izokvinolin- 5- il]- acetamid
N- [2- bromo- pirazolo [1,5- a] pirimidin- 2- karbonil)- 1,2,3,4- tetrahidro- izokvinolin- 5- il]- acetamid
N- [2- (6- kloro- pirazolo [1,5- a] pirimidin- 2- karbonil)- 1- metil- 1,2,3,4- tetrahidro- izokvinolin- 5- il]- acetamid
N- [2- (6- bromo- pirazolo [1,5- a] pirimidin- 2- karbonil)- 1- metil- 1,2,3,4- tetrahidro- izokvinolin- 5- il]- acetamid
N- [2- (6- kloro- pirazolo [1,5- a] pirimidin- 2- karbonil)- 1- metil- 1,2,3,4- tetrahidro- izokvinolin- 5- il]- acetamid
2- (6- bromo- pirazolo [1,5- a] pirimidin- 2- karbonil)- 1- metil- 1,2,3,4- tetrahidro- izokvinolin- 5- dimetilamid karboksilne kiseline
2- (6- kloro- pirazolo [1,5- a] pirimidin- 2- karbonil)- 1- metil- 1,2,3,4- tetrahidro- izokvinolin- 5- dimetilamid karboksilne kiseline
(6- bromo- pirazolo [1,5- a] pirimidin- 2- il) – (8- metil- 2,3,5,8- tetrahidro- 6H- 1,4- dioksa- 7- aza- fenantren- 7- il)- metanon
2- (6- bromo- pirazolo [1,5- a] pirimidin- 2- karbonil)- 1,2,3,4- tetrahidro- izokvinolin- 5- karbonitril
2- (6- bromo- pirazolo [1,5- a] pirimidin- 2- karbonil)- 1,2,3,4- tetrahidro- izokvinolin- 7- karbonitril
(6- bromo- pirazolo [1,5- a] pirimidin- 2- il) – (6- piridin- 4- il- 3,4- dihidro- 1H- izokvinolin- 2- il)- metanon
(6- kloro- pirazolo [1,5- a] pirimidin- 2- il) – (6- piridin- 4- il- 3,4- dihidro- 1H- izokvinolin- 2- il)- metanon
(6- kloro- pirazolo [1,5- a] pirimidin- 2- il) – (1- metil- 6- piridin- 4- il- 3,4- dihidro- 1H- izokvinolin- 2- il)- metanon
(6- bromo- pirazolo [1,5- a] pirimidin- 2- il) – (1- metil- 6- piridin- 4- il- 3,4- dihidro- 1H- izokvinolin- 2- il)- metanon
(6- bromo- pirazolo [1,5- a] pirimidin- 2- il) – (6- metil- 8,9- dihidro- 6H- [1,3] dioksolo [4,5- f] izokvinolin- 7- il)- metanon
(6- bromo- pirazolo [1,5- a] pirimidin- 2- il) – (1- metil- 5- piridin- 4- il- 3,4- dihidro- 1H- izokvinolin- 2- il)- metanon
(6- kloro- pirazolo [1,5- a] pirimidin- 2- il) – (1- metil- 5- piridin- 4- il- 3,4- dihidro- 1H- izokvinolin- 2- il)- metanon
(6- bromo- 3,4- dihidro- 1H- izokvinolin- 2- il) – (6- bromo- pirazolo [1,5- a] pirimidin- 2- il)- metanon
(6- bromo- pirazolo [1,5- a] pirimidin- 2- il) – (6- piridin- 2- il- 3,4- dihidro- 1H- izokvinolin- 2- il)- metanon
(6- bromo- pirazolo [1,5- a] pirimidin- 2- il) – (1- metil- 6- piridin- 2- il- 3,4- dihidro- 1H- izokvinolin- 2- il)- metanon
(6- kloro- pirazolo [1,5- a] pirimidin- 2- il) – (1- metil- 6- piridin- 2- il- 3,4- dihidro- 1H- izokvinolin- 2- il)- metanon
(6- kloro- pirazolo [1,5- a] pirimidin- 2- il) – (1- metil- 7- piridin- 2- il- 3,4- dihidro- 1H- izokvinolin- 2- il)- metanon
(5- bromo- 3,4- dihidro- 1H- izokvinolin- 2- il) - (6- bromo- pirazolo [1,5- a] pirimidin- 2- il)- metanon
(5- bromo- 3,4- dihidro- 1H- izokvinolin- 2- il) - (6- kloro- pirazolo [1,5- a] pirimidin- 2- il)- metanon
(6- bromo- pirazolo [1,5- a] pirimidin- 2- il) – (5- piridin- 2- il- 3,4- dihidro- 1H- izokvinolin- 2- il)- metanon
(6- bromo- pirazolo [1,5- a] pirimidin- 2- il) – [5- (2,4- dimetoksi- pirimidin- 5- il)- 1- metil- 3,4- dihidro- 1H- izokvinolin- 2- il)- metanon
(6- kloro- pirazolo [1,5- a] pirimidin- 2- il) – [5- (2,4- dimetoksi- pirimidin- 5- il)- 1- metil- 3,4- dihidro- 1H- izokvinolin- 2- il)- metanon
(6- bromo- pirazolo [1,5- a] pirimidin- 2- il) – [5- (2,6- dimetoksi- piridin- 3- il)- 1- metil- 3,4- dihidro- 1H- izokvinolin- 2- il]- metanon
(6- kloro- pirazolo [1,5- a] pirimidin- 2- il) – [5- (2,6- dimetoksi- piridin- 3- il)- 1- metil- 3,4- dihidro- 1H- izokvinolin- 2- il]- metanon
(6- bromo- pirazolo [1,5- a] pirimidin- 2- il) – [5- (6- fluoro- piridin- 3- il)- 1- metil- 3,4- dihidro- 1H- izokvinolin- 2- il]- metanon
(6- kloro- pirazolo [1,5- a] pirimidin- 2- il) – [5- (6- fluoro- piridin- 3- il)- 1- metil- 3,4- dihidro- 1H- izokvinolin- 2- il]- metanon
(6- bromo- pirazolo [1,5- a] pirimidin- 2- il) – [5- (2- metoksi- piridin- 3- il)- 1- metil- 3,4- dihidro- 1H- izokvinolin- 2- il]- metanon
(6- kloro- pirazolo [1,5- a] pirimidin- 2- il) – [5- (2- metoksi- piridin- 3- il)- 1- metil- 3,4- dihidro- 1H- izokvinolin- 2- il]- metanon
(6- kloro- pirazolo [1,5- a] pirimidin- 2- il) – [5- (6- metoksi- piridin- 3- il)- 1- metil- 3,4- dihidro- 1H- izokvinolin- 2- il]- metanon
(6- bromo- pirazolo [1,5- a] pirimidin- 2- il) – [5- (6- metoksi- piridin- 3- il)- 1- metil- 3,4- dihidro- 1H- izokvinolin- 2- il]- metanon
(6- bromo- pirazolo [1,5- a] pirimidin- 2- il) – [6- (2- metoksi- piridin- 3- il)- 1- metil- 3,4- dihidro- 1H- izokvinolin- 2- il]- metanon
(6- kloro- pirazolo [1,5- a] pirimidin- 2- il) – [6- (2- metoksi- piridin- 3- il)- 1- metil- 3,4- dihidro- 1H- izokvinolin- 2- il]- metanon
(6- bromo- pirazolo [1,5- a] pirimidin- 2- il) – [6- (2- fluoro- piridin- 3- il)- 1- metil- 3,4- dihidro- 1H- izokvinolin- 2- il]- metanon
(6- kloro- pirazolo [1,5- a] pirimidin- 2- il) – [6- (2- fluoro- piridin- 3- il)- 1- metil- 3,4- dihidro- 1H- izokvinolin- 2- il]- metanon
(6- bromo- pirazolo [1,5- a] pirimidin- 2- il) – [6- (6- fluoro- piridin- 3- il)- 1- metil- 3,4- dihidro- 1H- izokvinolin- 2- il]- metanon
(6- kloro- pirazolo [1,5- a] pirimidin- 2- il) – [6- (6- fluoro- piridin- 3- il)- 1- metil- 3,4- dihidro- 1H- izokvinolin- 2- il]- metanon
(6- bromo- pirazolo [1,5- a] pirimidin- 2- il) – [6- (2,6- dimetoksi- piridin- 3- il)- 1- metil- 3,4- dihidro- 1H- izokvinolin- 2- il]- metanon
(6- kloro- pirazolo [1,5- a] pirimidin- 2- il) – [6- (2,6- dimetoksi- piridin- 3- il)- 1- metil- 3,4- dihidro- 1H- izokvinolin- 2- il]- metanon
(6- bromo- pirazolo [1,5- a] pirimidin- 2- il) – [6- (2,4- dimetoksi- pirimidin- 5- il)- 1- metil- 3,4- dihidro- 1H- izokvinolin- 2- il]- metanon
(6- kloro- pirazolo [1,5- a] pirimidin- 2- il) – [6- (2,4- dimetoksi- pirimidin- 5- il)- 1- metil- 3,4- dihidro- 1H- izokvinolin- 2- il]- metanon
(6- kloro- pirazolo [1,5- a] pirimidin- 2- il) – [7- (6- metoksi- piridin- 3- il)- 1- metil- 3,4- dihidro- 1H- izokvinolin- 2- il]- metanon
(6- kloro- pirazolo [1,5- a] pirimidin- 2- il) – [7- (2- metoksi- piridin- 3- il)- 1- metil- 3,4- dihidro- 1H- izokvinolin- 2- il]- metanon
(6- bromo- pirazolo [1,5- a] pirimidin- 2- il) – [7- (2,4- dimetoksi- pirimidin- 5- il)- 1- metil- 3,4- dihidro- 1H- izokvinolin- 2- il]- metanon
(6- kloro- pirazolo [1,5- a] pirimidin- 2- il) – [7- (2,4- dimetoksi- pirimidin- 5- il)- 1- metil- 3,4- dihidro- 1H- izokvinolin- 2- il]- metanon
(6- bromo- pirazolo [1,5- a] pirimidin- 2- il) – [7- (2- fluoro- piridin- 3- il)- 1- metil- 3,4- dihidro- 1H- izokvinolin- 2- il]- metanon
(6- kloro- pirazolo [1,5- a] pirimidin- 2- il) – [7- (2- fluoro- piridin- 3- il)- 1- metil- 3,4- dihidro- 1H- izokvinolin- 2- il]- metanon
(6- bromo- pirazolo [1,5- a] pirimidin- 2- il) – [5- (2- fluoro- piridin- 3- il)- 1- metil- 3,4- dihidro- 1H- izokvinolin- 2- il]- metanon
(6- kloro- pirazolo [1,5- a] pirimidin- 2- il) – [5- (2- fluoro- piridin- 3- il)- 1- metil- 3,4- dihidro- 1H- izokvinolin- 2- il]- metanon
(6- bromo- pirazolo [1,5- a] pirimidin- 2- il) – (8- furan- 2- il- 1- metil- 3,4- dihidro- 1H- izokvinolin- 2- il)- metanon
(6- bromo- pirazolo [1,5- a] pirimidin- 2- il) – (7- furan- 2- il- 1- metil- 3,4- dihidro- 1H- izokvinolin- 2- il)- metanon
(6- bromo- pirazolo [1,5- a] pirimidin- 2- il) – (6- furan- 2- il- 1- metil- 3,4- dihidro- 1H- izokvinolin- 2- il)- metanon
(6- bromo- pirazolo [1,5- a] pirimidin- 2- il) – (5- furan- 2- il- 1- metil- 3,4- dihidro- 1H- izokvinolin- 2- il)- metanon
(6- bromo- pirazolo [1,5- a] pirimidin- 2- il) – [1- metil- 8- (5- metil- furan- 2- il)- 3,4- dihidro- 1H- izokvinolin- 2- il)- metanon
(6- bromo- pirazolo [1,5- a] pirimidin- 2- il) – [1- metil- 7- (5- metil- furan- 2- il)- 3,4- dihidro- 1H- izokvinolin- 2- il)- metanon
(6- bromo- pirazolo [1,5- a] pirimidin- 2- il) – [1- metil- 6- (5- metil- furan- 2- il)- 3,4- dihidro- 1H- izokvinolin- 2- il)- metanon
(6- bromo- pirazolo [1,5- a] pirimidin- 2- il) – [1- metil- 5- (5- metil- furan- 2- il)- 3,4- dihidro- 1H- izokvinolin- 2- il)- metanon
(6- bromo- pirazolo [1,5- a] pirimidin- 2- il) – (8- furan- 3- il- 1- metil- 3,4- dihidro- 1H- izokvinolin- 2- il)- metanon
(6- bromo- pirazolo [1,5- a] pirimidin- 2- il) – (7- furan- 3- il- 1- metil- 3,4- dihidro- 1H- izokvinolin- 2- il)- metanon
(6- bromo- pirazolo [1,5- a] pirimidin- 2- il) – (6- furan- 3- il- 1- metil- 3,4- dihidro- 1H- izokvinolin- 2- il)- metanon
(6- bromo- pirazolo [1,5- a] pirimidin- 2- il) – (5- furan- 3- il- 1- metil- 3,4- dihidro- 1H- izokvinolin- 2- il)- metanon
(6- bromo- pirazolo [1,5- a] pirimidin- 2- il) – [8- (3,5- dimetil- izoksazol- 4- il)- 1- metil- 3,4- dihidro- 1H- izokvinolin- 2- il]- metanon
(6- bromo- pirazolo [1,5- a] pirimidin- 2- il) – [7- (3,5- dimetil- izoksazol- 4- il)- 1- metil- 3,4- dihidro- 1H- izokvinolin- 2- il]- metanon
(6- bromo- pirazolo [1,5- a] pirimidin- 2- il) – [6- (3,5- dimetil- izoksazol- 4- il)- 1- metil- 3,4- dihidro- 1H- izokvinolin- 2- il]- metanon
(6- bromo- pirazolo [1,5- a] pirimidin- 2- il) – [5- (3,5- dimetil- izoksazol- 4- il)- 1- metil- 3,4- dihidro- 1H- izokvinolin- 2- il]- metanon
(6- bromo- pirazolo [1,5- a] pirimidin- 2- il) – [1- metil- 8- (1H- pirazol- 4- il)- 3,4- dihidro- 1H- izokvinolin- 2- il]- metanon
(6- bromo- pirazolo [1,5- a] pirimidin- 2- il) – [1- metil- 7- (1H- pirazol- 4- il)- 3,4- dihidro- 1H- izokvinolin- 2- il]- metanon
(6- bromo- pirazolo [1,5- a] pirimidin- 2- il) – [1- metil- 6- (1H- pirazol- 4- il)- 3,4- dihidro- 1H- izokvinolin- 2- il]- metanon
(6- bromo- pirazolo [1,5- a] pirimidin- 2- il) – [1- metil- 5- (1H- pirazol- 4- il)- 3,4- dihidro- 1H- izokvinolin- 2- il]- metanon
(6- bromo- pirazolo [1,5- a] pirimidin- 2- il) – [1- metil- 8- (1- metil- 1H- pirazol- 4- il)- 3,4- dihidro- 1H- izokvinolin- 2- il]- metanon
(6- bromo- pirazolo [1,5- a] pirimidin- 2- il) – [1- metil- 7- (1- metil- 1H- pirazol- 4- il)- 3,4- dihidro- 1H- izokvinolin- 2- il]- metanon
(6- bromo- pirazolo [1,5- a] pirimidin- 2- il) – [1- metil- 6- (1- metil- 1H- pirazol- 4- il)- 3,4- dihidro- 1H- izokvinolin- 2- il]- metanon
(6- bromo- pirazolo [1,5- a] pirimidin- 2- il) – [1- metil- 5- (1- metil- 1H- pirazol- 4- il)- 3,4- dihidro- 1H- izokvinolin- 2- il]- metanon
(6- bromo- pirazolo [1,5- a] pirimidin- 2- il) – [1- metil- 8- (3- metil- 1H- pirazol- 4- il)- 3,4- dihidro- 1H- izokvinolin- 2- il]- metanon
(6- bromo- pirazolo [1,5- a] pirimidin- 2- il) – [1- metil- 7- (3- metil- 1H- pirazol- 4- il)- 3,4- dihidro- 1H- izokvinolin- 2- il]- metanon
(6- bromo- pirazolo [1,5- a] pirimidin- 2- il) – [1- metil- 6- (3- metil- 1H- pirazol- 4- il)- 3,4- dihidro- 1H- izokvinolin- 2- il]- metanon
(6- bromo- pirazolo [1,5- a] pirimidin- 2- il) – [1- metil- 5- (3- metil- 1H- pirazol- 4- il)- 3,4- dihidro- 1H- izokvinolin- 2- il]- metanon
(6- bromo- pirazolo [1,5- a] pirimidin- 2- il) – [1- metil- 8- (2H- tetrazol- 5- il)- 3,4- dihidro- 1H- izokvinolin- 2- il]- metanon
(6- bromo- pirazolo [1,5- a] pirimidin- 2- il) – [1- metil- 7- (2H- tetrazol- 5- il)- 3,4- dihidro- 1H- izokvinolin- 2- il]- metanon
(6- bromo- pirazolo [1,5- a] pirimidin- 2- il) – [1- metil- 6- (2H- tetrazol- 5- il)- 3,4- dihidro- 1H- izokvinolin- 2- il]- metanon
(6- bromo- pirazolo [1,5- a] pirimidin- 2- il) – [1- metil- 5- (2H- tetrazol- 5- il)- 3,4- dihidro- 1H- izokvinolin- 2- il]- metanon
(6- bromo- pirazolo [1,5- a] pirimidin- 2- il) – (1- metil- 3,4- dihidro- 1H- [2,7] naftahidrin- 2- il)- metanon
(6- bromo- pirazolo [1,5- a] pirimidin- 2- il) – (1- metil- 3,4- dihidro- 1H- [2,6] naftahidrin- 2- il)- metanon
(6- bromo- pirazolo [1,5- a] pirimidin- 2- il) – (5- metil- 7,8- dihidro- 5H- pirido [4,3- d] pirimidin- 6- il)- metanon
(6- bromo- pirazolo [1,5- a] pirimidin- 2- il) – (8- metil- 5,8- dihidro- 6H- pirido [3,4- d] pirimidin - 7- il)- metanon
(6- bromo- pirazolo [1,5- a] pirimidin- 2- il) – (1- metil- 5- nitro- 3,4- dihidro- 1H- izokvinolin- 2- il)- metanon
(6- bromo- pirazolo [1,5- a] pirimidin- 2- il) – (1- metil- 6- nitro- 3,4- dihidro- 1H- izokvinolin- 2- il)- metanon
(6- bromo- pirazolo [1,5- a] pirimidin- 2- il) – (1- metil- 7- nitro- 3,4- dihidro- 1H- izokvinolin- 2- il)- metanon
(6- bromo- pirazolo [1,5- a] pirimidin- 2- il) – (1- metil- 8- nitro- 3,4- dihidro- 1H- izokvinolin- 2- il)- metanon
(6- bromo- pirazolo [1,5- a] pirimidin- 2- il) – (1- metil- 5- nitro- 3,4- dihidro- 1H- [2,7] naftahidrin - 2- il)- metanon
2- (6- bromo- pirazolo [1,5- a] pirimidin- 2- karbonil)- 1- metil- 1,2,3,4- tetrahidroizokvinolin- 5- karbontril
2- (6- bromo- pirazolo [1,5- a] pirimidin- 2- karbonil)- 1- metil- 1,2,3,4- tetrahidroizokvinolin- 5- metilni ester karboksilne kiseline
(6- bromo- pirazolo [1,5- a] pirimidin- 2- il)- (2,6- dimetil- 8,9- dihidro- 6H- 3- oksa- 1,7- diaza- ciklopenta[a]naftalen- 7- il)- metanon
(6- bromo- pirazolo [1,5- a] pirimidin- 2- il)- (4- metil- 1,4- dihidro- 2H- [3,7] fenantrolin- 3- il)- metanon
(6- bromo- pirazolo [1,5- a] pirimidin- 2- il)- (2,6- dimetil- 8,9- dihidro- 6H- tiazolo[4,5- f] izokvinolin- 7- il)- metanon
(6- bromo- pirazolo [1,5- a] pirimidin- 2- il)- (5- metansulfonil- 1- metil- 3,4- dihidro- 1H- izokvinolin- 2- il)- metanon
(6- bromo- pirazolo [1,5- a] pirimidin- 2- il)- (6- metansulfonil- 1- metil- 3,4- dihidro- 1H- izokvinolin- 2- il)- metanon
(6- bromo- pirazolo [1,5- a] pirimidin- 2- il)- (7- metansulfonil- 1- metil- 3,4- dihidro- 1H- izokvinolin- 2- il)- metanon
(6- bromo- pirazolo [1,5- a] pirimidin- 2- il)- (8- metansulfonil- 1- metil- 3,4- dihidro- 1H- izokvinolin- 2- il)- metanon
(6- bromo- pirazolo [1,5- a] pirimidin- 2- il)- (4,7- dimetil- 1,4,7,8,9,10- heksahidro- 2H- [3,7] fenantrolin- 3- il)- metanon
1- [2- (6- bromo- pirazolo [1,5- a] pirimidin- 2- karbonil)- 1- metil- 1,2,3,4- tetrahidro- izokvinolin- 5- il]- etanon
2- (6- bromo- pirazolo [1,5- a] pirimidin- 2- karbonil)- 1- metil- 1,2,3,4- tetrahidro- izokvinolin- 6- metilni ester karboksilne kiseline
2- (6- bromo- pirazolo [1,5- a] pirimidin- 2- karbonil)- 1- metil- 1,2,3,4- tetrahidro- izokvinolin- 7- metilni ester karboksilne kiseline
(6- bromo- pirazolo [1,5- a] pirimidin- 2- karbonil)- [1- metil- 5- (morfolin- 4- karbonil)- 3,4- dihidro- 1H- izokvinolin- 2- il]- metanon
(6- bromo- pirazolo [1,5- a] pirimidin- 2- karbonil)- [1- metil- 7- (morfolin- 4- karbonil)- 3,4- dihidro- 1H- izokvinolin- 2- il]- metanon
(6- bromo- pirazolo [1,5- a] pirimidin- 2- karbonil)- [1- metil- 6- (morfolin- 4- karbonil)- 3,4- dihidro- 1H- izokvinolin- 2- il]- metanon
(6- bromo- pirazolo [1,5- a] pirimidin- 2- karbonil)- (6- metil- 8,9- dihidro- 6H- furo [3,2- f] izokvinolin- 7- il]- metanon
(6- bromo- pirazolo [1,5- a] pirimidin- 2- karbonil)- (3,6- dimetil- 3,6,8,9- tetrahidropirolo [3,2- f] izokvinolin- 7- il]- metanon
(6- bromo- pirazolo [1,5- a] pirimidin- 2- karbonil)- (8- metil- 5,8- dihidro- 6H- furo[3,2- g]izokvinolin- 7- il]- metanon
7- (6- bromo- pirazolo [1,5- a] pirimidin- 2- karbonil)- 2,6- dimetil- 1,2,6,7,8,9- heksahidro- pirolo [3,4- f] izokvinolin- 3- on
7- (6- bromo- pirazolo [1,5- a] pirimidin- 2- karbonil)- 2,6- dimetil- 2,3,6,7,8,9- heksahidro- pirolo [3,4- f] izokvinolin- 1- on
(6- bromo- pirazolo [1,5- a] pirimidin- 2- il)- (6- dietilamino- 1- metil- 3,4- dihidro- 1H- izokvinolin- 2- il)- metanon
(6- bromo- pirazolo [1,5- a] pirimidin- 2- il)- (5- dietilamino- 1- metil- 3,4- dihidro- 1H- izokvinolin- 2- il)- metanon
(6- bromo- pirazolo [1,5- a] pirimidin- 2- il)- (8- dietilamino- 1- metil- 3,4- dihidro- 1H- izokvinolin- 2- il)- metanon
(6- bromo- pirazolo [1,5- a] pirimidin- 2- il)- (7- dietilamino- 1- metil- 3,4- dihidro- 1H- izokvinolin- 2- il)- metanon
(6- bromo- pirazolo [1,5- a] pirimidin- 2- il)- (6,7- difluoro- 1- metil- 3,4- dihidro- 1H- izokvinolin- 2- il)- metanon
(6- kloro- pirazolo [1,5- a] pirimidin- 2- il)- (6,7- difluoro- 1- metil- 3,4- dihidro- 1H- izokvinolin- 2- il)- metanon
(6- bromo- pirazolo [1,5- a] pirimidin- 2- il)- (6,7- dikloro- 1- metil- 3,4- dihidro- 1H- izokvinolin- 2- il)- metanon
(6- kloro- pirazolo [1,5- a] pirimidin- 2- il)- (6,7- dikloro- 1- metil- 3,4- dihidro- 1H- izokvinolin- 2- il)- metanon
(6- bromo- pirazolo [1,5- a] pirimidin- 2- il)- (6,7- dibromo- 1- metil- 3,4- dihidro- 1H- izokvinolin- 2- il)- metanon
(6- kloro- pirazolo [1,5- a] pirimidin- 2- il)- (6,7- dibromo- 1- metil- 3,4- dihidro- 1H- izokvinolin- 2- il)- metanon
(6- bromo- pirazolo [1,5- a] pirimidin- 2- il)- (1- metil- 7- morfolin- 4- il- 3,4- dihidro- 1H- izokvinolin- 2- il)- metanon
(6- kloro- pirazolo [1,5- a] pirimidin- 2- il)- (1- metil- 7- morfolin- 4- il- 3,4- dihidro- 1H- izokvinolin- 2- il)- metanon
(6- bromo- pirazolo [1,5- a] pirimidin- 2- il)- (1- metil- 8- morfolin- 4- il- 3,4- dihidro- 1H- izokvinolin- 2- il)- metanon
(6- kloro- pirazolo [1,5- a] pirimidin- 2- il)- (1- metil- 8- morfolin- 4- il- 3,4- dihidro- 1H- izokvinolin- 2- il)- metanon
(6- bromo- pirazolo [1,5- a] pirimidin- 2- il)- (1- metil- 6- morfolin- 4- il- 3,4- dihidro- 1H- izokvinolin- 2- il)- metanon
(6- kloro- pirazolo [1,5- a] pirimidin- 2- il)- (1- metil- 6- morfolin- 4- il- 3,4- dihidro- 1H- izokvinolin- 2- il)- metanon
(6- bromo- pirazolo [1,5- a] pirimidin- 2- il)- (1- metil- 5- morfolin- 4- il- 3,4- dihidro- 1H- izokvinolin- 2- il)- metanon
(6- kloro- pirazolo [1,5- a] pirimidin- 2- il)- (1- metil- 5- morfolin- 4- il- 3,4- dihidro- 1H- izokvinolin- 2- il)- metanon
(6- bromo- pirazolo [1,5- a] pirimidin- 2- il)- (1- metil- 7- piperidin- 1- il- 3,4- dihidro- 1H- izokvinolin- 2- il)- metanon
(6- kloro- pirazolo [1,5- a] pirimidin- 2- il)- (1- metil- 7- piperidin- 1- il- 3,4- dihidro- 1H- izokvinolin- 2- il)- metanon
(6- bromo- pirazolo [1,5- a] pirimidin- 2- il)- (1- metil- 7- pirolidin- 1- il- 3,4- dihidro- 1H- izokvinolin- 2- il)- metanon
(6- kloro- pirazolo [1,5- a] pirimidin- 2- il)- (1- metil- 7- pirolidin- 1- il- 3,4- dihidro- 1H- izokvinolin- 2- il)- metanon.
11. Spojevi iz formule (I) temeljem bilo kojeg od zahtjeva 1 do 10 i spoj (6- bromo- pirazolo [1,5- a] pirimidin- 2- il)- (3,4- dihidro- 1H- izokvinolin- 2- il)- metanon i svi njihovi optički izomeri, farmaceutski prihvatljive soli, hidrati, otopine ili polimorfi za uporabu kao lijek.
12. Uporaba spoja iz formule (I) definirane jednim od zahtjeva 1 do 10 ili spoja (6- bromo- pirazolo [1,5- a] pirimidin- 2- il)- (3,4- dihidro- 1H- izokvinolin- 2- il)- metanon ili njihovih optičkih izomera, farmaceutski prihvatljivih soli, hidrata, otopina ili polimorfa za pripremu lijeka.
13. Uporaba spoja temeljem zahtjeva 12 za pripremu lijeka za sprječavanje i/ili liječenje stanja ili bolesti izabranih od: Alzheimerove bolesti, Creutzfeld-Jakobovog sindroma/bolesti, goveđe spongiformne encefalopatije (BSE), infekcija povezanih sa prionima, bolesti koje uključuju mitohondrijsku disfunkciju, bolesti koje uključuju 10-amiloide i/ili tautopatije, Downovog sindroma, jetrene encefalopatije, Huntingtonove bolesti, bolesti motoričkih neurona, amiotrofijske lateralne skleroze (ALS), olivoponto-cerebelarne atrofije, postoperativnog kognitivnog deficita (POCD), sistemskog lupusa eritematosus, sistemske skleroze, Sjogrenovog sindroma, neuronalne ceroidne lipofuscinoze, neurodegenerativne cerebralne ataksije, Parkinsonove bolesti, Parkinsonove demencije, blagog kognitivnog oštećenja, kognitivnih deficita u različitim oblicima blagih kognitivnih oštećenja, kognitivnih deficita u različitim oblicima demencije, demencije pugilistica, vaskularne demencije i demencije čeonog režnja, kognitivnih oštećenja, teškoća pri učenju, ozljeda očiju, bolesti očiju, poremećaja očiju, glaukoma, retinopatije, makularne degeneracije, ozljeda glave ili mozga ili leđne moždine, trauma glave ili mozga ili leđne moždine, trauma, hipoglikemije, hipoksije, perinatalne hipoksije, ishemije, ishemije kao posljedice srčanog udara ili bypass operacije ili transplantacije, konvulzija, epileptičkih konvulzija, epilepsije, epilepsije temporalnog režnja, miokloničke epilepsije, inzulta unutarnjeg uha, inzulta unutarnjeg uha u tinitusu, tinitusa, inzulta unutarnjeg uha uzrokovanim zvukom ili lijekom, tinitusa uzrokovanog zvukom ili lijekom, dikineze uzrokovane od L-dopa, dikineze uzrokovane od L-dopa kod terapije Parkinsonove bolesti, diskineze, diskineze kod Huntingtonove bolesti, diskineze uzrokovane lijekom, diskineze uzrokovane neurolepsijom, diskineze uzrokovane haloperidolom, diskineze uzrokovane dopaminomimetikom, koree, Huntingtonove koree, atetozije, distonije, stereotipije, balizma, tardivne diskineze, poremećaja tika, tortikoličnog spazmodiskusa, blefarospazma, fokalne i općenite distonije, nistagmusa, nasljedne cerebralne ataksije, kortikobazalne degeneracije, tremora (drhtavice), esencijalnog tremora, zloporabe, ovisnosti, ovisnosti o nikotinu, nikotinske zloporabe, ovisnosti o alkoholu, alkoholne zloporabe, ovisnosti o opijatima, zloporabe opijata, ovisnosti o kokainu, zloporabe kokaina, ovisnosti o amfetaminima, zloporabe amfetamina, poremećaja tjeskobe, paničnim poremećajima, poremećajima tjeskobe i panike, poremećaja socijalne tjeskobe (SAD), poremećaja nedostatka pažnje i hiperaktivnosti (ADHD), sindroma nedostatka pažnje (ADS), sindroma nemirnih nogu (RLS), hiperaktivnosti kod djece, autizma, demencije, demencije kod Alzheimerove bolesti, demencije kod Korsakovljevog sindroma, Korsakovljevog sindroma, vaskularne demencije, demencije povezane sa HIV infekcijama, HIV-1 encefalopatije, AIDS encefalopatije, kompleksa AIDS demencije, demencije povezane sa AIDS-om, poremećaja teške depresije, teške depresije, depresije, depresije koja je posljedica infekcije Boma virusom, bipolarnog manično-depresivnog poremećaja, otpornosti na lijekove, otpornosti na opioidne lijekove, poremećaja kretanja, krhkog-X sindroma, sindroma iritabilnog kolona (IBS), migrene, multiple skleroze (MS), spazma mišića, bolova, kroničnih bolova, akutnih bolova, inflamatornih bolova, neuropatskih bolova, dijabetičkih neuropatskih bolova (DNP), bolova povezanih sa reumatičnim artritisom, alodinijom, hiperalgezijom, nociceptivnim bolovima, bolovima kod raka, post-traumatskim stresnim poremećajem (PTSP), shizofrenije, pozitivnih ili kognitivnih ili negativnih simptoma shizofrenije, spasticiteta, Touretteovog sindroma, urinarne inkontinencije, povraćanja, stanja svrbeža, svrbeža (pruritisa), poremećaja spavanja, poremećaja mokrenja, neuromuskularnih poremećaja u donjem urinarnom traktu, gastroezofagealnog sindroma refluksa (GERD), gastrointestinalne disfunkcije, bolesti donjeg ezofagealnog sfinktera (LES), funkcionalnih gastrointestinalnih poremećaja, dispepsije, regurgitacije, infekcija respiratornog trakta, nervozne bulimije, kroničnog laringitisa, astme, astme povezane sa refluksom, bolesti pluća, poremećaja ishrane, gojaznosti, poremećaja povezanih sa gojaznosti, zloporabe gojaznosti, ovisnosti o hrani, poremećaja prejedanja, agorafobije, općenitih poremećaja tjeskobe, opsesivno-kompulzivnog poremećaja, poremećaja panike, post-traumatskog stresnog poremećaja, socijalnih fobija, fobičnih poremećaja, tjeskobnih poremećaja izazvanih tvarima, poremećaja zablude, shizoafektivnog poremećaja, shizofreniformnog poremećaja, psihotičnog poremećaja izazvanog tvarima, ili delirija; inhibicija rasta tumorskih stanica, migracije, invazije, adhezije i toksičnosti u periferalnom tkivu, periferalnom živčanom sustavu i CNS-u; neoplazije, hiperplazije, displazije, raka, karcinoma, sarkoma, raka ždrijela, karcinoma rožnatih stanica (SCC), karcinoma oralnih rožnatih stanica (SCC), raka pluća, adenokarcinoma pluća, raka dojke, raka prostate, raka želuca, raka jetre, raka debelog crijeva, kolorektalnog raka, rabdomiosarkoma, tumora na mozgu, tumora živčanog tkiva, glioma, malignog glioma, astroglioma, neuroglioma, neuroblastoma, glioblastoma, meduloblastoma, raka kože, melanoma, malignog melanoma, neoplazme epitele, limfoma, mijeloma, Hodgkinove bolesti, Burkittovog limfoma, leukemije, timoma i drugih tumora.
14. Uporaba spoja temeljem zahtjeva 12 ili njegovog optičkog izomera, farmaceutski prihvatljive soli, hidrata, otopine i polimorfa za pripremu lijeka za liječenje ili sprječavanje nekih od slijedećih stanja i bolesti: kroničnih bolova, neuropatskih bolova, dijabetičkih neuropatskih bolova (DNP), bolova kod raka, bolova povezanih sa reumatskim artritisom, bolova kod upale, diskineze izazvane sa L-dopa, dopaminomimetički izazvane diskineze, diskineze izazvane sa L-dopa kod terapije Parkinsonove bolesti, dopaminomimetički izazvane diskineze kod terapije Parkinsonove bolesti, tardivne diskineze, Parkinsonove bolesti, poremećaja tjeskobe, paničnih poremećaja, poremećaja tjeskobe i panike, poremećaja socijalne tjeskobe (SAD), općenitih tjeskobnih poremećaja, poremećaja tjeskobe izazvanih tvarima, poremećaja ishrane, gojaznosti, poremećaja prejedanja, Huntingtonove koree, epilepsije, Alzheimerove bolesti, pozitivnih i negativnih simptoma shizofrenije, kognitivnih oštećenja, funkcionalnih gastrointestinalnih poremećaja, bolesti gastroezofagealnog refluksa (GERD), migrene, sindroma iritablinog kolona (IBS), ili za kognitivna poboljšanja i/ili neurozaštitu.
15. Farmaceutski spoj koji kao aktivne tvari sadrži barem jednu of formula (I) kako su definirane bilo kojem od zahtjeva 1 do 10 ili spoj (6- bromo- pirazolo [1,5- a] pirimidin- 2- il) – (3,4- dihidro- 1H- izokvinolin- 2- il)- metanon ili njihove optičke izomere, farmaceutski prihvatljive soli, hidrate, otopine ili polimorfe, zajedno sa jednim ili više farmaceutski prihvatljivih ekscipijenata.
16. Farmaceutski spoj koji sadrži barem dvije različite aktivne tvari, koje sadrže barem jedan spoj iz formule (I) kako je definirana bilo kojim od zahtjeva 1 do 10 ili njihovih optičkih izomera, farmaceutski prihvatljivih soli, hidrata, otopina ili polimorfa, i koje sadrže barem jedan NMDA-antagonist, zajedno sa jednim ili više farmaceutski prihvatljivih ekscipijenata.
17. Postupak za sintezu spoja formule (I)
[image]
pri čemu
Y1 predstavlja N ili C-,
Y2 predstavlja N ili C-,
Y3 predstavlja N ili C-,
Y4 predstavlja N ili C-,
pri čemu barem dvije od skupina Y1 do Y4 označavaju atom ugljika,
R1 predstavlja kloro ili bromo;
R2 i R3 svaki zasebno predstavljaju vodik, C1-6alkil, C3-7cikloalkil ili trifluorometil; ili
R2 i R3 oba zajednosa atomom ugljika iz prstena predstavljaju karbonilnu skupinu; R4 i R5 svaki zasebno predstavljaju vodik, C1-6alkil, C3-7cikloalkil ili trifluorometil; ili
R4 i R5 oba zajednosa atomom ugljika iz prstena predstavljaju karbonilnu skupinu; R6 i R7 zasebno predstavljaju vodik, C1-6alkil, C3-7cikloalkil ili trifluorometil; ili
R6 i R7 oba zajednosa atomom ugljika iz prstena predstavljaju karbonilnu skupinu;R2 i R3 zajedno sa R6 R7 mogu također tvoriti bivalentni radikal iz skupine CH2-CH2 ili CH2-O;
R10 i R11 odvojeno predstavljaju vodik, halogen, amino, hidroksi, nitro, cijano, trifluorometil, trifluorometoksi, aril, C1-6alkil, C3-7cikloalkil, C2-6alkenil, C2-6alkinil, C1-6alkoksi, C3-7-cikloalkiloksi, C2-6alkeniloksi, C2-6alkiniloksi, heteroaril, heterociklil, ariloksi, heteroariloksi, heterocikliloksi, C1-6alkilamino, di-C1-6alkilamino, C3-7-cikloalkilamino, di-C3-7-cikloalkilamino, C1-6alkil-C3-7-cikloalkilamino, C2-6alkenilamino, C2-6alkinilamino, di-C2-6alkenilamino, di-C2-6alkinilamino, C1-6alkil-C2-6alkenilamino, C1-6alkil-C2-6-alkinilamino, C2-6alkenil-C3-7-cikloalkilamino, C2-6alkinil-C3-7-cikloalkilamino, C2-6alkenil-C2-6-alkinilamino, arilamino, diarilamino, aril-C1-6alkilamino, aril-C2-6alkenilamino, aril-C2-6alkinilamino, aril-C3-7-cikloalkilamino, heteroarilamino, diheteroarilamino, heteroaril-C1-6alkilamino, heteroaril-C2-6alkenilamino, heteroaril-C2-6alkinilamino, heteroaril-C3-7-cikloalkilamino, heteroarilarilamino, heterociklilamino, diheterociklilamino, heterociklil-C1-6alkilamino, heterociklil-C2-6alkenilamino, heterociklil-C2-6alkinilamino, heterociklil-C3-7-cikloalkilamino, heterociklilarilamino, heterociklilhetero-arilamino, acil, aciloksi, acilamino, C1-6alkoksikarbonil, C3-7-cikloalkoksi-karbonil, C2-6alkeniloksikarbonil, C2-6alkiniloksikarbonil, ariloksikarbonil, heteroariloksikarbonil, heterocikliloksikarbonil, aminokarbonil, C1-6alkilamino-karbonil, di-C1-6alkilaminokarbonil, C3-7-cikloalkilaminokarbonil, di-C3-7-cikloalkilaminokarbonil, C1-6alkil-C3-7-cikloalkilaminokarbonil, C2-6alkenil-aminokarbonil, C2-6alkinil-aminokarbonil, di-C2-6alkenilaminokarbonil, di-C2-6alkinilaminokarbonil, C1-6alkil-C2-6-alkenilaminokarbonil, C1-6alkil-C2-6-alkinil-aminokarbonil, C2-6alkenil-C3-7-cikloalkilaminokarbonil, C2-6alkinil-C3-7-cikloalkilaminokarbonil, C2-6alkenil-C2-6-alkinilaminokarbonil, arilaminokarbonil, diarilaminokarbonil, aril-C1-6alkilaminokarbonil, aril-C2-6alkenilaminokarbonil, aril-C2-6alkinilaminokarbonil, aril-C3-7-cikloalkilaminokarbonil, heteroarilaminokarbonil, diheteroarilaminokarbonil, heteroaril-C1-6alkilaminokarbonil, heteroaril-C2-6alkenilaminokarbonil, heteroaril-C2-6alkinilaminokarbonil, heteroaril-C3-7-cikloalkilaminokarbonil, heteroarilarilaminokarbonil, heterociklilaminokarbonil, diheterociklilaminokarbonil, heterociklil-C1-6alkilaminokarbonil, heterociklil-C2-6alkenilaminokarbonil, heterociklil-C2-6alkinilaminokarbonil, heterociklil-C3-7-cikloalkilaminokarbonil, heterociklilarilaminokarbonil, heterociklilheteroarilaminokarbonil, C1-6alkilsulfinil, C3-7cikloalkilsulfinil, C2-6alkenilsulfinil, arilsulfinil, heteroarilsulfinil, heterociklilsulfinil, C1-6alkilsulfonil, C3-7-cikloalkilsulfonil, C2-6alkenilsulfonil, C2-6alkinilsulfonil, arilsulfonil, heteroarilsulfonil, heterociklilsulfonil, C1-6alkilsulfonilamino, ili arilsulfonilamino;
ili R10 i R11 zajedno sa dva atoma ugljika koji ih nose predstavljaju heteroaril koji ima 5 ili 6 članova prstena ili heterociklilnu skupinu koja ima 5 ili 6 članova prstena, koja može biti zamijenjena s jednom od slijedećih skupina: halogen, hidroksi, nitro, cijano, trifluorometil, trifluorometoksi, C1-6alkil i C1-6alkoksi, naročito putem metila;
i njihovi optički izomeri, farmaceutski prihvatljive soli, hidrati, otopine i polimorfi
pri čemu se spoj iz formule (II)
[image]
nalazi u mješavini etanola i vode i tretiran sa hidrokloričnom kiselinom, nakon čega slijedi reakcija sa H2NNHCOOCH3 kako bi se dobio spoj iz Formule (III)
[image]
koji reagira sa spojem iz Formule (IV)
[image]
kako bi se dobio spoj iz formule (V)
[image]
koji se hidrolizira u kiselim uvjetima kako bi se dobio spoj iz formule (VI)
[image]
koji se tretira sa aminom iz formule (VII)
[image]
u prisutnosti agensa za zgušnjavanje, kako bi se dobio spoj iz formule (I), koji se pretvara, po želji, u farmaceutski prihvatljivu sol, hidrat, otopinu ili polimorf.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US83582006P | 2006-08-04 | 2006-08-04 | |
US87754406P | 2006-12-28 | 2006-12-28 | |
PCT/EP2007/058060 WO2008015269A1 (en) | 2006-08-04 | 2007-08-03 | Substituted pyrazolopyrimidines, a process for their preparation and their use as medicine |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20110128T1 true HRP20110128T1 (hr) | 2011-03-31 |
Family
ID=38710494
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HR20110128T HRP20110128T1 (hr) | 2006-08-04 | 2011-02-23 | Substituirani pirazolopirimidini, postupak njihove pripreme i njihova upotreba kao lijek |
Country Status (21)
Country | Link |
---|---|
US (4) | US7947689B2 (hr) |
EP (3) | EP2295439A1 (hr) |
JP (2) | JP2009545569A (hr) |
KR (1) | KR20090047450A (hr) |
AR (3) | AR062210A1 (hr) |
AT (2) | ATE488520T1 (hr) |
AU (2) | AU2007280429A1 (hr) |
BR (2) | BRPI0714622A2 (hr) |
CA (2) | CA2659876A1 (hr) |
CY (1) | CY1112003T1 (hr) |
DE (2) | DE602007010640D1 (hr) |
DK (1) | DK2054416T3 (hr) |
HR (1) | HRP20110128T1 (hr) |
IL (2) | IL196008A0 (hr) |
MX (2) | MX2009000919A (hr) |
PL (1) | PL2054416T3 (hr) |
PT (1) | PT2054416E (hr) |
RU (2) | RU2009107688A (hr) |
TW (3) | TW200815432A (hr) |
WO (3) | WO2008015270A1 (hr) |
ZA (1) | ZA200810605B (hr) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008056176A1 (en) * | 2006-11-10 | 2008-05-15 | Scottish Biomedical Limited | Pyrazolopyrimidines as phosphodiesterase inhibitors |
HK1136565A1 (en) * | 2007-03-31 | 2010-07-02 | Intervet Int Bv | Processes for making zilpaterol and salts thereof |
EP2090576A1 (en) * | 2008-02-01 | 2009-08-19 | Merz Pharma GmbH & Co.KGaA | 6-halo-pyrazolo[1,5-a]pyridines, a process for their preparation and their use as metabotropic glutamate receptor (mGluR) modulators |
RU2496494C2 (ru) | 2008-06-30 | 2013-10-27 | Новартис Аг | КОМБИНАЦИИ, СОДЕРЖАЩИЕ МОДУЛЯТОРЫ mGluR, ДЛЯ ЛЕЧЕНИЯ БОЛЕЗНИ ПАРКИНСОНА |
JP2013512216A (ja) | 2009-11-25 | 2013-04-11 | メルツ・ファルマ・ゲゼルシヤフト・ミト・ベシュレンクテル・ハフツング・ウント・コンパニー・コマンデイトゲゼルシヤフト・アウフ・アクティーン | 置換ピラゾロピリミジン類の結晶形 |
CA2820262A1 (en) | 2010-12-08 | 2012-06-14 | Vanderbilt University | Bicyclic pyrazole compounds as allosteric modulators of mglur5 receptors |
US8865725B2 (en) | 2011-03-15 | 2014-10-21 | Vanderbilt University | Substituted imidazopyrimidin-5(6H)-ones as allosteric modulators of MGLUR5 receptors |
CA2830220A1 (en) * | 2011-03-15 | 2012-09-20 | Vanderbilt University | Substituted imidazopyrimidin-5(6h)-ones as allosteric modulators of mglur5 receptors |
WO2012139876A1 (en) | 2011-04-14 | 2012-10-18 | Merz Pharma Gmbh & Co. Kgaa | Enteric formulations of metabotropic glutamate receptor modulators |
US8791108B2 (en) | 2011-08-18 | 2014-07-29 | Bristol-Myers Squibb Company | Inhibitors of human immunodeficiency virus replication |
WO2013087808A1 (en) | 2011-12-15 | 2013-06-20 | Merz Pharma Gmbh & Co. Kgaa | Pharmaceutical composition comprising a pyrazolopyrimidme and cyclodextrin |
WO2013087815A1 (en) | 2011-12-15 | 2013-06-20 | Merz Pharma Gmbh & Co. Kgaa | Liquid pharmaceutical composition containing a pyrazolopyrimidine derivative and pharmaceutical uses thereof |
US9006235B2 (en) | 2012-03-06 | 2015-04-14 | Bristol-Myers Squibb Company | Inhibitors of human immunodeficiency virus replication |
EP2831074B1 (en) * | 2012-03-29 | 2016-09-14 | Boehringer Ingelheim International GmbH | Novel pyrazolopyrimidines as metabotropic glutamate 5 receptor antagonists for the treatment of psychiatric diseases |
JO3407B1 (ar) * | 2012-05-31 | 2019-10-20 | Eisai R&D Man Co Ltd | مركبات رباعي هيدرو بيرازولو بيريميدين |
WO2014035707A1 (en) * | 2012-08-25 | 2014-03-06 | The Johns Hopkins University | Gapdh cascade inhibitor compounds and methods of use and treatment of stress induced disorders including mental illness |
EP2958915B1 (en) | 2013-02-19 | 2017-07-05 | Pfizer Inc | Azabenzimidazole compounds as inhibitors of pde4 isozymes for the treatment of cns and other disorders |
WO2014164467A1 (en) | 2013-03-13 | 2014-10-09 | Bristol-Myers Squibb Company | Inhibitors of human immunodeficiency virus replication |
WO2014164428A1 (en) | 2013-03-13 | 2014-10-09 | Bristol-Myers Squibb Company | Inhibitors of human immunodeficiency virus replication |
CN105008369B (zh) | 2013-03-14 | 2017-07-11 | 百时美施贵宝公司 | 人类免疫缺陷病毒复制抑制剂 |
EP3036219A4 (en) * | 2013-06-04 | 2017-08-23 | Temple University Of The Commonwealth System Of Higher Education | Novel beta lactams as modulators of glutamate uptake and methods for use thereof |
MX2016005994A (es) | 2013-11-05 | 2017-01-11 | Univ Temple | Anifífilos policatónicos como agentes antimicrobianos. |
US10398142B2 (en) | 2013-11-05 | 2019-09-03 | Temple University Of The Commonwealth System Of Higher Education | Polycationic amphiphiles as antimicrobial agents |
GB201320905D0 (en) | 2013-11-27 | 2014-01-08 | Takeda Pharmaceutical | Therapeutic compounds |
US9273067B2 (en) | 2014-02-19 | 2016-03-01 | Bristol-Myers Squibb Company | Pyrazolopyrimidine macrocycles as inhibitors of human immunodeficiency virus replication |
WO2016012896A1 (en) | 2014-07-24 | 2016-01-28 | Pfizer Inc. | Pyrazolopyrimidine compounds |
JP6506833B2 (ja) | 2014-08-06 | 2019-04-24 | ファイザー・インク | イミダゾピリダジン化合物 |
CA3222584A1 (en) | 2016-01-27 | 2017-08-03 | Universitat Zurich | Use of gabaa receptor modulators for treatment of itch |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH603545A5 (hr) | 1972-04-20 | 1978-08-31 | Merz & Co | |
GB1383409A (en) * | 1972-09-09 | 1974-02-12 | Pfizer Ltd | Derivatives of 2-amino- and 4-amino-quinazoline and pharmaceutical compositions containing them |
US3988339A (en) * | 1974-02-08 | 1976-10-26 | Smithkline Corporation | Pharmaceutical compositions and methods of inhibiting phenylethanolamine N-methyltransferase |
US3974283A (en) * | 1974-03-18 | 1976-08-10 | Sandoz, Inc. | N-substituted-4-T-butyl-1-pyridinethiocarboxamides and their use for treatment of inflammation or pain |
NZ190915A (en) * | 1978-07-31 | 1984-07-31 | Hoffmann La Roche | Oxadiazolotriazine derivatives and pharmaceutical compositions |
DE2856393C2 (de) | 1978-12-27 | 1983-04-28 | Merz + Co GmbH & Co, 6000 Frankfurt | Arzneimittel zur Behandlung von Morbus Parkinson |
SU768177A1 (ru) * | 1979-04-23 | 1985-08-07 | МГУ им.М.В.Ломоносова | Способ получени ( @ )-(-) или ( @ )-(+)-1=метил-1,2,3,4-тетрагидроизохинолина |
ZA803591B (en) * | 1979-07-09 | 1981-06-24 | American Cyanamid Co | Substituted pyrazolo(1,5-a)pyrimidines |
US4340597A (en) * | 1981-04-13 | 1982-07-20 | Schering Corporation | 1-Substituted-4-aryl-1,2,5,6-tetrahydro and hexahydropyridines |
DE3308554A1 (de) * | 1983-03-10 | 1984-09-13 | Hoechst Ag, 6230 Frankfurt | 1-/1,3-dioxolan-2-ylmethyl)-azole, ihre salze, verfahren zu ihrer herstellung und ihre verwendung |
WO1989005643A1 (en) * | 1987-12-18 | 1989-06-29 | Pfizer Inc. | Heterocyclic-substituted quinoline-carboxylic acids |
DE10299048I2 (de) | 1989-04-14 | 2006-07-13 | Merz Pharma Gmbh & Co Kgaa | Verwendung von Adamantan-Derivaten zur Pr{vention und Behandlung der cerebralen Isch{mie |
US6177443B1 (en) * | 1997-03-07 | 2001-01-23 | Novo Nordisk A/S | 4,5,6,7-tetrahydro-thieno[3, 2-C]pyridine derivatives, their preparation and use |
US6071966A (en) | 1997-06-30 | 2000-06-06 | Merz + Co. Gmbh & Co. | 1-amino-alkylcyclohexane NMDA receptor antagonists |
IL133235A (en) | 1997-06-30 | 2004-02-19 | Merz Pharma Gmbh & Co Kgaa | 1-amino-alkylcyclohexane nmda receptor antagonists and pharmaceutical compositions comprising them |
DE19732589A1 (de) * | 1997-07-29 | 1999-02-04 | Huels Chemische Werke Ag | Verfahren zur Herstellung von 1,2,3,6-tetrahydro-2,2,6,6-tetramethylpyridin |
FR2769313B1 (fr) * | 1997-10-06 | 2000-04-21 | Sanofi Sa | Derives d'esters hydroxyacetiques, leur procede de preparation et leur utilisation comme intermediaires de synthese |
NZ505207A (en) | 1997-11-21 | 2003-10-31 | Nps Pharma Inc | Metabotropic glutamate receptor antagonists for treating central nervous system diseases |
ATE290527T1 (de) * | 1997-12-25 | 2005-03-15 | Meiji Seika Kaisha | Tetrahydrobenzindol-derivate |
CN1261098C (zh) | 1998-08-28 | 2006-06-28 | 西奥斯股份有限公司 | p38-α激酶的抑制剂 |
US20020049223A1 (en) | 1999-11-05 | 2002-04-25 | Elmore Steven W. | Quinoline and naphthyridine carboxylic acid antibacterials |
MXPA02006474A (es) * | 1999-12-28 | 2002-11-29 | Eisai Co Ltd | Compuestos heterociclicos que contienen sulfonamida. |
GB0110338D0 (en) | 2001-04-27 | 2001-06-20 | Sb Pharmco Inc | Novel processes |
GB0118752D0 (en) * | 2001-08-01 | 2001-09-26 | Pfizer Ltd | Process for the production of quinazolines |
EP1506196B1 (en) * | 2001-11-01 | 2012-01-18 | Icagen, Inc. | Pyrazolopyrimidines as sodium channel inhibitors |
AU2003227437A1 (en) * | 2002-04-23 | 2003-11-10 | Shionogi And Co., Ltd. | PYRAZOLO(1,5-a)PYRIMIDINE DERIVATIVE AND NAD(P)H OXIDASE INHIBITOR CONTAINING THE SAME |
WO2003101993A1 (en) | 2002-06-04 | 2003-12-11 | Neogenesis Pharmaceuticals, Inc. | Pyrazolo` 1,5a! pyrimidine compounds as antiviral agents |
WO2004014902A2 (en) * | 2002-08-09 | 2004-02-19 | Astrazeneca Ab | Compounds having an activity at metabotropic glutamate receptors |
WO2004087153A2 (en) | 2003-03-28 | 2004-10-14 | Chiron Corporation | Use of organic compounds for immunopotentiation |
JP2006522750A (ja) | 2003-04-11 | 2006-10-05 | ノボ ノルディスク アクティーゼルスカブ | 代謝性症候群ならびに関連の疾患および障害を治療するために、11β−ヒドロキシステロイドデヒドロゲナーゼ1型阻害剤および抗高血圧剤を使用する併用療法 |
WO2004089471A2 (en) | 2003-04-11 | 2004-10-21 | Novo Nordisk A/S | NEW PYRAZOLO[1,5-a] PYRIMIDINES DERIVATIVES AND PHARMACEUTICAL USE THEREOF |
JP2006522744A (ja) | 2003-04-11 | 2006-10-05 | ノボ ノルディスク アクティーゼルスカブ | グルココルチコイド受容体アゴニスト療法に伴う副作用を最小化するための、11β−ヒドロキシステロイドデヒドロゲナーゼ1型阻害剤およびグルココルチコイド受容体アゴニストを使用する併用療法 |
EP1773880A4 (en) | 2004-06-08 | 2009-09-09 | Novartis Vaccines & Diagnostic | ENV POLYPEPTIDE COMPLEXES AND METHOD FOR THEIR USE |
WO2006015737A1 (de) | 2004-08-02 | 2006-02-16 | Schwarz Pharma Ag | Carboxamide des indolizins und seiner aza- und diazaderivate |
JP2008527031A (ja) | 2005-01-19 | 2008-07-24 | バイオリポックス エービー | 炎症の治療に有用なピロロピリジン誘導体 |
-
2007
- 2007-08-03 EP EP10190596A patent/EP2295439A1/en not_active Withdrawn
- 2007-08-03 WO PCT/EP2007/058061 patent/WO2008015270A1/en active Application Filing
- 2007-08-03 WO PCT/EP2007/058060 patent/WO2008015269A1/en active Application Filing
- 2007-08-03 TW TW096128661A patent/TW200815432A/zh unknown
- 2007-08-03 EP EP07788197A patent/EP2054421B1/en active Active
- 2007-08-03 AU AU2007280429A patent/AU2007280429A1/en not_active Abandoned
- 2007-08-03 JP JP2009522285A patent/JP2009545569A/ja not_active Abandoned
- 2007-08-03 AT AT07788197T patent/ATE488520T1/de active
- 2007-08-03 AR ARP070103439A patent/AR062210A1/es not_active Application Discontinuation
- 2007-08-03 AR ARP070103437A patent/AR063680A1/es not_active Application Discontinuation
- 2007-08-03 WO PCT/EP2007/058062 patent/WO2008015271A1/en active Application Filing
- 2007-08-03 DK DK07788196.9T patent/DK2054416T3/da active
- 2007-08-03 RU RU2009107688/04A patent/RU2009107688A/ru not_active Application Discontinuation
- 2007-08-03 TW TW096128665A patent/TW200823215A/zh unknown
- 2007-08-03 TW TW096128671A patent/TWI399376B/zh not_active IP Right Cessation
- 2007-08-03 AT AT07788196T patent/ATE494289T1/de active
- 2007-08-03 EP EP07788196.9A patent/EP2054416B8/en active Active
- 2007-08-03 PT PT07788196T patent/PT2054416E/pt unknown
- 2007-08-03 RU RU2009107686/04A patent/RU2450004C2/ru not_active IP Right Cessation
- 2007-08-03 JP JP2009522284A patent/JP2010500288A/ja active Pending
- 2007-08-03 DE DE602007010640T patent/DE602007010640D1/de active Active
- 2007-08-03 BR BRPI0714622-1A patent/BRPI0714622A2/pt not_active IP Right Cessation
- 2007-08-03 CA CA002659876A patent/CA2659876A1/en not_active Abandoned
- 2007-08-03 PL PL07788196T patent/PL2054416T3/pl unknown
- 2007-08-03 US US11/890,211 patent/US7947689B2/en not_active Expired - Fee Related
- 2007-08-03 US US11/890,230 patent/US20080032998A1/en not_active Abandoned
- 2007-08-03 DE DE602007011773T patent/DE602007011773D1/de active Active
- 2007-08-03 BR BRPI0714766-0A patent/BRPI0714766A2/pt not_active IP Right Cessation
- 2007-08-03 MX MX2009000919A patent/MX2009000919A/es active IP Right Grant
- 2007-08-03 KR KR1020097002224A patent/KR20090047450A/ko not_active Application Discontinuation
- 2007-08-03 CA CA002659871A patent/CA2659871A1/en not_active Abandoned
- 2007-08-03 AU AU2007280428A patent/AU2007280428B2/en not_active Ceased
- 2007-08-03 AR ARP070103438A patent/AR062209A1/es unknown
- 2007-08-03 US US11/890,199 patent/US7985753B2/en not_active Expired - Fee Related
- 2007-08-03 MX MX2009001036A patent/MX2009001036A/es active IP Right Grant
-
2008
- 2008-12-15 ZA ZA2008/10605A patent/ZA200810605B/en unknown
- 2008-12-17 IL IL196008A patent/IL196008A0/en unknown
- 2008-12-17 IL IL196007A patent/IL196007A0/en unknown
-
2011
- 2011-02-23 HR HR20110128T patent/HRP20110128T1/hr unknown
- 2011-03-21 CY CY20111100303T patent/CY1112003T1/el unknown
- 2011-05-03 US US13/068,150 patent/US20110212956A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20110128T1 (hr) | Substituirani pirazolopirimidini, postupak njihove pripreme i njihova upotreba kao lijek | |
US8889684B2 (en) | Azaindolylphenyl sulfonamides as serine/threonine kinase inhibitors | |
AU2009210197A1 (en) | Pyrazolopyrimidines, a process for their preparation and their use as medicine | |
KR101793807B1 (ko) | 단백질 키나제 억제제로서의 융합된 헤테로시클릭 화합물 | |
CA3165864A1 (en) | Substituted tricyclic compounds | |
AU2008343065B2 (en) | 5-anilinoimidazopyridines and methods of use | |
AU2013213474B2 (en) | New indolizine derivatives, method for preparing same and pharmaceutical compositions containing same | |
WO2009095253A1 (en) | 6-halo-pyrazolo[1, 5-a]pyridines, a process for their preparation and their use as metabotropic glutamate receptor (mglur) modulators | |
KR20210099611A (ko) | 헤테로 방향족 유도체 조절제, 이의 제조방법 및 용도 | |
US20130023531A1 (en) | Pyrimido[5,4-d]pyrimidylamino phenyl sulfonamides as serine/threonine kinase inhibitors | |
JP2017501187A (ja) | キナーゼ阻害剤及びその使用 | |
AU2018381004A1 (en) | Heterocyclic compounds as PRMT5 inhibitors | |
CN105294737A (zh) | Cdk类小分子抑制剂的化合物及其用途 | |
AU2021373162A1 (en) | Pyrazolopyridazinone compound, and pharmaceutical composition and use thereof | |
ES2356576T3 (es) | Pirazolopirimidinas, un proceso para su preparación y su uso como medicamento. | |
WO2024052512A1 (en) | Heterocyclic derivatives as janus kinase inhibitors | |
OA16963A (fr) | Nouveaux dérivés d'indolizine, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent. |